https://www.ematologiainprogress.it/lassenza-di-espressione-di-cd38-caratterizza-un-sottogruppo-di-leucemia-linfoblastica-acuta-ph-like-con-prognosi-particolarmente-infausta/ 2026-07-13T11:44:57+00:00 monthly 0.8 https://www.ematologiainprogress.it/focus-sul-mieloma-multiplo-belantamab-mafodotin/ 2026-07-10T12:29:00+00:00 monthly 0.8 https://www.ematologiainprogress.it/efficacia-di-hma-piu-venetoclax-verso-chemioterapia-intensiva-nei-pazienti-con-lma-ad-altissimo-rischio-citogenetico/ 2026-07-03T16:51:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-sindrome-vexas-vacuoles-e1-enzyme-x-linked-autoinflammatory-somatic/ 2026-06-22T11:07:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/venetoclax-in-associazione-a-citarabina-ad-alto-dosaggio-e-a-mitoxantrone-come-trattamento-di-salvataggio-per-la-leucemia-mieloide-acuta-recidivante-o-refrattaria-relax-trial-uno-studio-multicentri/ 2026-06-19T10:34:14+00:00 monthly 0.8 https://www.ematologiainprogress.it/crispr-cas13d-rivela-nuove-vulnerabilita-nel-mieloma-multiplo-legate-a-specifiche-isoforme-di-lncrna/ 2026-05-18T08:42:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/quizartinib-una-nuova-opzione-terapeutica-per-la-leucemia-acuta-mieloide-flt3-positiva/ 2026-05-04T10:42:23+00:00 monthly 0.8 https://www.ematologiainprogress.it/cpx-351vsdaunorubicinacitarabinagemtuzumab/ 2026-04-20T10:43:28+00:00 monthly 0.8 https://www.ematologiainprogress.it/vexasinternationalworkshop/ 2026-03-30T15:46:00+00:00 monthly 0.8 https://www.ematologiainprogress.it/hematology-pills/ 2026-07-20T10:54:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/disordini-del-metabolismo-del-ferro/ 2026-03-16T14:06:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/cellule-car-t/ 2026-02-19T10:27:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2025-i-risultati-dello-studio-paradigm/ 2026-04-01T12:51:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-linfatica-cronica-terapia-target-di-durata-fissa-a-confronto-con-la-terapia-continuativa/ 2026-07-01T17:24:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/alla-radice-sindrome-vexas-vacuoles-e1-enzyme-x-linked-autoinflammatory-somatic-infiammazione-e-resilienza-delle-cellule-staminali-mutate-sono-i-meccanismi-chiave-della-malattia/ 2026-02-09T08:55:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/update-sulla-malattia-di-castleman-multicentrica-idiopatica-imcd-dalla-ricerca-alla-clinica-anche-con-il-supporto-dellintelligenza-artificiale-ia/ 2026-01-27T11:05:22+00:00 monthly 0.8 https://www.ematologiainprogress.it/sindromi-mieloproliferative-croniche/ 2026-01-27T11:37:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-rischio-genetico-ma-non-lo-stato-di-remissione-detemina-loutcome-del-trapianto-allogenico-nella-lam-esiti-a-lungo-termine-dello-studio-asap/ 2025-12-19T10:27:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamenti-sulla-trombocitopenia-immune-dal-congresso-sie-2025/ 2025-12-02T09:26:34+00:00 monthly 0.8 https://www.ematologiainprogress.it/mieloma-multiplo-le-novita-dagli-oral-abstract-della-sie-2025/ 2025-11-24T11:12:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/mieloma-multiplo/ 2025-10-30T22:29:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/arsenic-trioxide-and-all-trans-retinoic-acid-combination-therapy-for-the-treatment-of-high-risk-acute-promyelocytic-leukemia-results-from-the-apollo-trial/ 2025-09-24T14:24:10+00:00 monthly 0.8 https://www.ematologiainprogress.it/risultati-a-lungo-termine-dello-studio-agile-azacitidina-piu-ivosidenib-vs-placebo-nei-pazienti-con-lam-idh1-mutata-di-nuova-diagnosi/ 2025-09-22T16:16:33+00:00 monthly 0.8 https://www.ematologiainprogress.it/focus-on-malattia-di-gaucher-associata-a-gammopatia-monoclonale-di-incerto-significato-mgus-e-mieloma-multiplo/ 2025-08-26T10:10:10+00:00 monthly 0.8 https://www.ematologiainprogress.it/dichiarazione-accessibilita/ 2025-08-02T15:01:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2024-piastrinopenia-immune/ 2026-04-01T12:51:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-piastrinopenia-immune-itp/ 2025-07-28T14:50:23+00:00 monthly 0.8 https://www.ematologiainprogress.it/aipit-patients-day/ 2025-07-08T12:35:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/foxo1-e-un-fattore-trascrizionale-ferro-sensibile-che-regola-lomeostasi-sistemica-del-ferro/ 2025-07-30T08:35:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/menin-inhibition-with-revumenib-for-npm1-mutated-npm1m-relapsed-or-refractory-acute-myeloid-leukemia-augment-101/ 2025-07-01T11:29:34+00:00 monthly 0.8 https://www.ematologiainprogress.it/ph-acute-lymphoblastic-leukemia-25-years-of-progress/ 2025-07-01T12:17:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/lo-studio-enhance-3-venetoclax-e-azacitidina-piu-magrolimab-o-placebo-per-i-pazienti-con-aml-di-nuova-diagnosi-non-eleggibili-per-un-trattamento-intensivo/ 2025-07-30T08:34:39+00:00 monthly 0.8 https://www.ematologiainprogress.it/studio-di-fase-2-con-cpx-351-combinato-a-venetoclax-nella-leucemia-acuta-mieliode-ricaduta-refrattaria/ 2025-07-01T12:17:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-views-events/ 2025-06-04T13:49:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/programma-eha-2025/ 2025-07-01T12:17:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-mieloide-cronica-3/ 2025-07-01T12:17:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/caratteristiche-e-outcome-della-leucemia-mieloide-acuta-con-riarrangiamento-di-kmt2a-di-nuova-diagnosi/ 2025-07-01T12:17:55+00:00 monthly 0.8 https://www.ematologiainprogress.it/blinatumomab-nella-leucemia-linfoblastica-acuta-a-cellule-b-a-rischio-standard-del-bambino-2/ 2025-07-01T12:17:57+00:00 monthly 0.8 https://www.ematologiainprogress.it/piastrinopenia-immune-itp-e-rischio-tromboembolico-venoso-ed-arterioso-2/ 2025-07-01T12:17:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2025/ 2025-07-01T12:18:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/bruin-cll-321-il-primo-studio-randomizzato-nella-llc-recidivata-refrattaria-precedentemente-trattata-con-inibitori-btk-2/ 2025-07-01T12:18:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/i-registri-di-patologia-nellitp/ 2025-07-01T12:18:07+00:00 monthly 0.8 https://www.ematologiainprogress.it/valutazione-prognostica-a-lungo-termine-secondo-la-classificazione-eln-di-pazienti-con-leucemia-mieloide-acuta-2/ 2025-07-01T12:18:09+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-e-ricadute-applicative-dellash-2024/ 2026-04-01T12:51:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/bruin-cll-321-il-primo-studio-randomizzato-nella-llc-recidivata-refrattaria-precedentemente-trattata-con-inibitori-btk/ 2026-04-01T12:51:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/vantaggio-di-pfs-e-os-con-la-terapia-target-di-prima-linea-nella-llc-risultati-dello-studio-amolify/ 2026-04-01T12:51:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/risultati-dello-studio-felix-che-utilizza-il-prodotto-car-t-obe-cel-in-pazienti-adulti-con-leucemia-acuta-linfoblastica-b-recidivati-o-refrattari-2/ 2025-07-01T12:21:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuovi-farmaci-per-il-trattamento-della-piastrinopenia-immune-itp/ 2025-07-01T12:25:19+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2024-selezione-degli-abstract-piu-rilevanti-sulla-leucemia-acuta-mieloide/ 2026-04-01T12:51:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-radioterapia-mediastinica-di-consolidamento-puo-essere-eliminata-nei-linfomi-primitivi-del-mediastino-pmbl-risultati-finali-del-trial-ielsg-37-2/ 2025-07-01T12:17:09+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2024-metabolismo-e-patologie-del-ferro/ 2026-04-01T12:51:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-mieloide-cronica/ 2025-02-18T12:34:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/blinatumomab-nella-leucemia-linfoblastica-acuta-a-cellule-b-a-rischio-standard-del-bambino/ 2025-02-14T09:33:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/risultati-dello-studio-felix-che-utilizza-il-prodotto-car-t-obe-cel-in-pazienti-adulti-con-leucemia-acuta-linfoblastica-b-recidivati-o-refrattari/ 2025-02-07T14:22:41+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-ash-2024-foa/ 2026-04-01T12:51:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/piastrinopenia-immune-itp-e-rischio-tromboembolico-venoso-ed-arterioso/ 2025-01-29T16:06:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-ash-2024-chiaretti/ 2026-04-01T12:51:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-ash-2024-ansuinelli/ 2026-04-01T12:51:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-ash-2024-cerrano/ 2026-04-01T12:51:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-ash-2024-piciocchi/ 2026-04-01T12:51:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/new-campus-cll/ 2024-12-13T10:10:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/report-convegno-nazionale-target-cll-2024-scelta-e-gestione-della-terapia-milano-21-ottobre-2024/ 2025-06-04T15:43:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/neoplasie-istiocitiche-miste-unentita-in-via-di-definizione/ 2024-11-11T17:40:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/le-malattie-rare/ 2024-11-11T17:39:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/resoconto-dal-51-congresso-nazionale-sie-focus-sulla-itp/ 2025-06-04T15:43:33+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-radioterapia-mediastinica-di-consolidamento-puo-essere-eliminata-nei-linfomi-primitivi-del-mediastino-pmbl-risultati-finali-del-trial-ielsg-37/ 2024-11-11T15:32:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/epcidina/ 2025-07-08T12:44:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-somministrazione-di-ferro-per-via-endovenosa-induce-un-rapido-aumento-del-contenuto-miocardico-di-ferro-attraverso-un-nuovo-pathway/ 2024-10-08T18:07:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-linfatica-cronica/ 2024-10-07T15:22:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/significato-della-malattia-misurabile-residua-negli-adulti-affetti-da-leucemia-acuta-linfoblastica-philadelphia-positiva-uno-studio-graaph-2014/ 2024-09-25T17:11:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/ruolo-di-blinatumomab-in-pazienti-mrd-negativi-nella-lal/ 2024-09-23T12:44:00+00:00 monthly 0.8 https://www.ematologiainprogress.it/combinazione-di-dasatinib-e-venetoclax-come-terapia-di-prima-linea-in-pazienti-affetti-da-leucemia-mieloide-cronica/ 2024-09-16T17:10:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/asciminib-in-pazienti-affetti-da-leucemia-mieloide-cronica-di-nuova-diagnosi/ 2024-09-16T17:06:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/revumenib-per-la-leucemia-acuta-recidivata-o-refrattaria-con-riarrangiamento-di-kmt2a-augment-101/ 2024-09-16T16:43:41+00:00 monthly 0.8 https://www.ematologiainprogress.it/alti-tassi-di-malattia-minima-residua-non-rilevabile-con-la-combinazione-pirtobrutinib-venetoclax-e-obinutuzumab-nella-terapia-di-prima-linea-della-leucemia-linfatica-cronica/ 2024-09-16T16:31:10+00:00 monthly 0.8 https://www.ematologiainprogress.it/diagnosi-fattori-prognostici-e-valutazione-della-all-negli-adulti-raccomandazioni-eln-2024/ 2024-08-29T18:23:20+00:00 monthly 0.8 https://www.ematologiainprogress.it/policitemia-vera-novita-dal-congresso-eha-2024/ 2025-06-04T15:44:20+00:00 monthly 0.8 https://www.ematologiainprogress.it/lepatochina-fibrinogen-like-protein-1-fgl1-e-un-nuovo-potente-soppressore-di-epcidina/ 2024-10-08T17:48:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/report-dalleuropean-iron-club-eic-meeting-toulouse-23-26-aprile-2024/ 2025-06-04T15:44:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-trapianto-nellanemia-falciforme-lesperienza-del-centro-di-dodoma-tanzania/ 2024-07-29T15:18:19+00:00 monthly 0.8 https://www.ematologiainprogress.it/gilteritinib-come-mantenimento-post-trapianto-per-la-leucemia-mieloide-acuta-con-mutazione-flt3-itd/ 2024-06-05T15:13:22+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamenti-di-diagnostica-molecolare-in-ematologia-2024/ 2024-07-29T15:23:21+00:00 monthly 0.8 https://www.ematologiainprogress.it/citofluorimetria-nella-malattia-residua-misurabile/ 2024-06-05T15:18:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-fish-nel-mieloma-multiplo-stratificazione-del-rischio/ 2024-06-05T15:17:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/piattaforme-di-diagnosi-in-ematologia/ 2024-09-16T15:12:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/decitabina-e-cedazuridina-piu-venetoclax-un-regime-orale-per-i-pazienti-anziani-o-unfit-con-leucemia-mieloide-acuta/ 2024-04-22T15:24:39+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-sulla-terapia-dei-linfomi-2023-e-novita-dallash-2023-focus-sui-linfomi-diffusi-a-grandi-cellule-b/ 2026-04-01T12:51:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/car-t-anti-bcma-idecabtagene-vicleucel-e-ciltacabtagene-autoleucel-aggiornamenti-dalla-letteratura/ 2025-06-25T11:44:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2023-leucemia-acuta-linfoblastica/ 2026-04-01T12:51:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/follow-up-a-lungo-termine-dello-studio-viale-a-venetoclax-e-azacitidina-nei-pazienti-con-leucemia-mieloide-acuta-di-nuova-diagnosi-non-eleggibili-per-chemioterapia-intensiva/ 2024-04-08T12:20:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/patients-with-chronic-lymphocytic-leukemia-carrying-t1419-display-a-distinctive-transcriptomic-profile-and-adverse-outcome-which-might-be-overcome-continuous-therapy-with-btk-inhibitors-an-italia/ 2024-03-11T14:50:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-sul-metabolismo-e-le-patologie-del-ferro-allash-2023/ 2026-04-01T12:51:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/trattamento-a-bassa-intensita-basato-su-venetoclax-nella-failure-molecolare-della-lam-npm1-mutata/ 2024-03-01T15:51:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/pubblicato-il-nuovo-handbook-gitmo/ 2024-07-04T11:15:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/xpo1-mutations-identify-early-stage-cll-characterized-by-shorter-time-to-first-treatment-and-enhanced-bcr-signalling/ 2024-03-11T14:52:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/approfondimento-su-fostamatinib-un-inibitore-della-syk-spleen-tyrosine-kinase-meccanismo-dazione-e-ruolo-nel-trattamento-dellitp/ 2024-02-22T17:24:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/itp-primaria-approfondimento-e-novita-nelluso-degli-agonisti-del-recettore-della-trombopoietina-tpo-ra/ 2024-04-22T15:48:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/follow-up-a-lungo-termine-del-trattamento-di-prima-linea-con-dasatinib-e-blinatumomab-per-pazienti-con-leucemia-acuta-linfoblastica-ph-delladulto/ 2024-02-20T16:08:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-regime-flag-ida-gemtuzumab-ozogamicin-migliora-la-event-free-survival-nei-pazienti-giovani-con-lam-di-nuova-diagnosi-e-la-overall-survival-nei-pazienti-con-mutazioni-di-npm1-e-flt3/ 2024-02-20T17:02:26+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2023-selezione-degli-abstract-piu-rilevanti-sulla-leucemia-acuta-mieloide-parte-2/ 2026-04-01T12:51:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2023-selezione-degli-abstract-piu-rilevanti-sulla-leucemia-acuta-mieloide-parte-1/ 2026-04-01T12:51:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/protocollo-dasatinib-blinatumomab-negli-adulti-con-lal-ph/ 2024-02-12T16:23:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/combinazione-di-venetoclax-ed-agenti-ipometilanti-nella-leucemia-acuta-mieloide-di-nuova-diagnosi-predittori-molecolari-di-risposta-e-sopravvivenza-in-301-pazienti/ 2024-02-02T17:15:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/venetoclax-annulla-limpatto-prognostico-delle-mutazioni-nei-geni-del-fattore-di-splicing-nella-leucemia-acuta-mieloide-di-nuova-diagnosi/ 2024-01-31T16:41:48+00:00 monthly 0.8 https://www.ematologiainprogress.it/studio-del-profilo-genomico-della-leucemia-acuta-linfoblastica-associata-a-sindrome-di-down/ 2024-01-23T17:22:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/efficacia-e-tollerabilita-di-inotuzumab-ozogamicin-come-terapia-di-induzione-nella-leucemia-linfoblastica-acuta-b-philadelphia-negativa-cd22-positiva-in-pazienti-55-anni-risultati-finali-del-trial-i/ 2024-01-23T17:15:26+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-zanubrutinib-a-confronto-con-ibrutinib-nella-leucemia-linfatica-cronica-recidivata-refrattaria/ 2026-04-01T12:51:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-leucemia-linfatica-cronica-le-terapie-con-i-nuovi-farmaci-migliorano-la-sopravvivenza-globale-rispetto-alla-chemioimmunoterapia/ 2026-04-01T12:51:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-daicongressi/ 2026-04-01T12:52:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/neoplasia-a-cellule-dendritiche-plasmacitoidi-blastiche/ 2024-02-28T13:12:01+00:00 monthly 0.8 https://www.ematologiainprogress.it/caratteristiche-e-outcome-clinico-dei-pazienti-con-leucemia-acuta-mieloide-con-inv3q21q26-2-o-t33q21q26-2/ 2023-12-07T10:57:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/piastrinopenia-immune-novita-dal-congresso-eha-2023/ 2023-11-20T17:22:28+00:00 monthly 0.8 https://www.ematologiainprogress.it/the-history-of-allogeneic-transplantation/ 2023-12-20T14:47:18+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-in-tema-di-ferro-alleha-2023-riassunte-in-hemasphere/ 2023-11-16T15:02:40+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-linfatica-cronica-sostenibilita-delle-terapie-con-inibitori-di-btk-e-con-linibitore-di-bcl2-venetoclax/ 2023-12-20T11:27:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/quizartinib-piu-chemioterapia-in-pazienti-di-nuova-diagnosis-con-aml-flt3-internal-tandem-duplication-positiva-quantum-first-uno-studio-randomizzato-di-fase-3-in-doppio-cieco/ 2023-11-16T12:53:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/impatto-clinico-nella-lmc/ 2025-02-17T14:35:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/impatto-della-mrd-negli-studi-clinici/ 2025-02-17T14:35:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/sviluppi-tecnologici/ 2025-02-17T14:35:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-biopsia-liquida-puo-avere-un-ruolo/ 2025-02-17T14:35:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/flow-mrd-nella-lam/ 2025-02-17T14:35:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/mrd-nella-real-life/ 2025-02-17T14:35:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/le-car-t-potrebbero-avere-un-ruolo/ 2025-02-17T14:35:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/mrd-highlights/ 2023-10-30T09:11:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/mrd-come-endpoint-nella-real-life/ 2025-02-17T14:35:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/impatto-clinico-nelle-lal/ 2025-02-17T14:35:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/mrd-in-oncoematologia-malattia-residua-minima-misurabile/ 2025-02-17T14:35:23+00:00 monthly 0.8 https://www.ematologiainprogress.it/modulation-of-apoptosis-to-enhance-car-t-immunotherapy/ 2023-12-20T13:08:34+00:00 monthly 0.8 https://www.ematologiainprogress.it/towards-off-the-shelf-adoptive-immunotherapy-of-leukemia/ 2023-12-20T12:59:10+00:00 monthly 0.8 https://www.ematologiainprogress.it/update-on-cell-based-therapeutics-in-aml-from-car-t-cells-to-dual-car-cik-cells/ 2023-12-20T12:44:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/cellule-car-t-old/ 2026-02-19T09:06:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-acuta-linfoide/ 2024-07-29T16:29:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-mieloide-acuta/ 2023-08-22T14:44:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/pre-clinical-models-as-platform-for-testing-immune-therapies/ 2023-10-25T17:10:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/risultati-di-uno-studio-real-world-sullefficacia-di-tisa-cel-in-pazienti-pediatrici-e-giovani-adulti-con-leucemia-linfoblastica-acuta-b-cd19-positiva/ 2023-07-31T14:59:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/bispecific-antibodies-for-r-r-dlbcl/ 2023-10-25T16:51:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/update-on-antibody-based-therapeutics-and-molecular-targets-in-aml-preclinical-development-and-clinical-progresses/ 2023-08-01T16:07:14+00:00 monthly 0.8 https://www.ematologiainprogress.it/immunotherapy-in-hematological-malignancies-cuneo-2023/ 2023-07-28T13:52:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/immunotherapy-in-hematological-malignancies-2023/ 2023-10-25T16:15:19+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamenti-sul-mieloma-multiplo-dal-congresso-eha-2023/ 2023-07-17T17:38:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-prof-robin-foa-ha-ricevuto-a-francoforte-leha-2023-jose-carreras-award/ 2023-07-04T12:10:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-ferro-modula-lespressione-ematologica-dei-disordini-mieloproliferativi-jak2-positivi/ 2023-06-16T12:20:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-follow-up-a-cinque-anni-dello-studio-zuma-1-supporta-il-potenziale-curativo-di-axicabtagene-ciloleucel-nel-linfoma-refrattario-a-grandi-cellule-b/ 2023-06-12T16:43:26+00:00 monthly 0.8 https://www.ematologiainprogress.it/trattamento-con-blinatumomab-nella-leucemia-acuta-linfoblastica-dellinfante-con-riarrangiamento-del-gene-kmt2a/ 2023-06-14T10:45:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamento-sulla-terapia-genica-in-emofilia-a/ 2023-05-23T11:53:18+00:00 monthly 0.8 https://www.ematologiainprogress.it/adattamento-dei-meccanismi-ematologici-nella-popolazione-andina/ 2023-05-16T10:12:23+00:00 monthly 0.8 https://www.ematologiainprogress.it/malattia-di-castleman/ 2023-05-11T16:28:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/terapia-genica-in-emofilia-b/ 2023-05-08T17:47:03+00:00 monthly 0.8 https://www.ematologiainprogress.it/trattamento-con-car-t-ide-cel-nel-mieloma-multiplo-recidivato-e-refrattario/ 2023-04-17T16:41:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/the-folate-story-a-vitamin-under-the-microscope/ 2023-04-11T12:53:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfomi-a-grandi-cellule-anaplastiche/ 2023-03-29T10:51:28+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfomi-a-cellule-t-periferiche-non-altrimenti-specificati/ 2023-05-25T12:43:39+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfomi-a-cellule-t-periferiche-di-tipo-nodale/ 2023-03-29T10:52:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/al-via-la-nuova-sezione-sui-linfomi-t/ 2023-03-20T14:00:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/avanzamenti-nella-regolazione-dell-omeostasi-del-ferro/ 2023-03-10T12:24:42+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-ruolo-principale-del-recettore-della-transferrina-epatico-non-solo-iron-uptake-bensi-regolazione-di-epcidina-tramite-il-legame-con-la-proteina-hfe-potenziali-applicazioni-tera/ 2023-03-06T16:12:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-leucemie-linfoblastiche-acute/ 2024-01-19T14:59:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/metabolismo-del-ferro-novita-dallash-2022/ 2026-04-01T12:51:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-patologie-della-coagulazione/ 2024-01-19T14:59:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-leucemia-mieloide-acuta/ 2024-01-19T14:59:00+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-mieloma-multiplo/ 2024-01-19T14:58:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/piastrinopenia-immune-novita-dallash-2022/ 2026-04-01T12:51:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/lipossia-e-le-basse-temperature-aumentano-i-livelli-di-transferrina-inducendo-ipercoagulabilita-in-alta-quota/ 2023-01-27T13:09:35+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-leucemia-mieloide-cronica/ 2024-01-19T14:58:48+00:00 monthly 0.8 https://www.ematologiainprogress.it/le-istiocitosi/ 2023-01-19T17:48:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-leucemia-linfatica-cronica/ 2024-01-19T14:58:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-linfomi/ 2024-01-19T14:58:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/luspatercept-per-i-pazienti-talassemici-non-trasfusione-dipendenti/ 2022-12-07T10:59:18+00:00 monthly 0.8 https://www.ematologiainprogress.it/teclistamab-nel-mieloma-multiplo/ 2022-12-07T11:01:23+00:00 monthly 0.8 https://www.ematologiainprogress.it/car-t-non-solo-in-ematologia/ 2022-12-07T10:18:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/lal-ph-futuro-senza-chemioterapia-sistemica-e-trapianto/ 2022-12-07T09:25:23+00:00 monthly 0.8 https://www.ematologiainprogress.it/prof-daniel-catovsky-1937-2022/ 2022-12-06T18:10:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-in-tema-di-emocromatosi-un-nuovo-tipo-di-emocromatosi/ 2022-11-23T13:23:14+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-in-tema-di-emocromatosi-classificazione-aggiornata-e-raccomandazioni-dalla-bioiron-society/ 2022-11-23T13:19:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-sulla-terapia-dei-linfomi-non-hodgkin-2022/ 2022-11-16T17:58:57+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-mieloide-acuta-e-gilteritinib/ 2022-11-23T13:30:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfomi-presente-e-futuro/ 2022-11-04T16:39:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/classificazione-dei-linfomi-2/ 2022-11-04T16:39:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/management-di-ponatinib-in-italia-unanalisi-dei-registri-aifa/ 2022-11-02T17:20:00+00:00 monthly 0.8 https://www.ematologiainprogress.it/le-car-nk-iduo-sono-in-grado-di-determinare-risposte-durature-e-prevenire-lescape-antigenico-nei-linfomi-non-hodgkin-e-nella-leucemia-acuta-linfoblastica-a-cellule-b/ 2022-10-28T10:23:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/52764-2/ 2022-10-20T14:55:42+00:00 monthly 0.8 https://www.ematologiainprogress.it/genetica-della-sindrome-di-richter/ 2022-10-19T23:04:07+00:00 monthly 0.8 https://www.ematologiainprogress.it/einp-piu-vs-einp-plus/ 2022-11-09T13:18:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/presentazione-einp-piu/ 2022-11-09T13:18:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/ruolo-del-trapianto-allogenico-di-cellule-staminali-nella-leucemia-acuta-linfoblastica-ph-in-prima-remissione-completa/ 2022-10-17T17:28:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/einppiu/ 2023-11-14T12:07:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-patologie-trombotiche-a-falanga/ 2022-10-05T15:36:42+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-car-t-a-di-rocco-2/ 2022-10-05T15:19:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-disordini-mieloproliferativi-cronici-ph-a-vannucchi/ 2022-10-05T15:11:10+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-gammopatie-monoclonali-m-t-petrucci/ 2022-10-05T15:02:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-leucemia-linfatica-cronica-a-cuneo/ 2022-10-05T14:52:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-linfomi-m-martelli/ 2022-10-05T13:15:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/metabolismo-del-ferro-highlights-dalleuropean-iron-club-2022/ 2022-09-20T12:59:57+00:00 monthly 0.8 https://www.ematologiainprogress.it/ferritina/ 2022-09-02T16:46:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/funzioni-della-transferrina-e-dei-suoi-recettori/ 2022-09-02T16:29:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/ferrodeplezione/ 2022-09-02T16:08:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/fabbisogno-del-ferro/ 2022-09-02T15:48:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-dal-congresso-eha-2022-piastrinopenia-immune/ 2022-08-03T17:26:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/order-confirmation/ 2022-07-29T21:57:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/order-failed/ 2022-07-29T21:57:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/checkout/ 2022-07-29T21:57:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuova-classificazione-who-della-leucemia-acuta-mieloide-lam/ 2022-07-20T18:04:35+00:00 monthly 0.8 https://www.ematologiainprogress.it/enasidenib-vs-il-trattamento-convenzionale-nei-pazienti-con-lam-idh2-mutata-recidivata-refrattaria-uno-studio-randomizzato-di-fase-3/ 2022-07-13T16:00:13+00:00 monthly 0.8 https://www.ematologiainprogress.it/sindrome-di-richter/ 2022-08-02T16:18:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-prolinfocitica-pll/ 2022-07-21T16:17:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/complicanze-infettive-nella-llc/ 2022-07-21T15:04:40+00:00 monthly 0.8 https://www.ematologiainprogress.it/complicanze-infettive-nella-llc-inclusa-linfezione-covid-19/ 2022-07-21T15:05:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/un-modello-di-sopravvivenza-dinamico-a-3-fattori-per-la-leucemia-acuta-mieloide-che-tiene-conto-della-risposta-alla-chemioterapia-di-induzione/ 2022-07-05T10:36:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/follow-up-dei-pazienti-con-lam-r-r-flt3-positiva-trattati-con-gilteritinib-nello-studio-admiral/ 2022-07-04T15:57:22+00:00 monthly 0.8 https://www.ematologiainprogress.it/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-la-review-pubblicata-sul-nejm/ 2022-06-28T17:08:32+00:00 monthly 0.8 https://www.ematologiainprogress.it/axicabtagene-ciloleucel-in-prima-linea-nei-linfomi-a-grandi-cellule-b-ad-alto-rischio-risultati-preliminari-dello-studio-zuma-12/ 2022-05-30T18:43:22+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfoma-non-hodgkin/ 2024-07-29T16:19:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/ivosidenib-and-azacitidine-in-idh1-mutated-acute-myeloid-leukemia/ 2022-06-15T11:40:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfoma-di-hodgkin/ 2024-07-29T16:18:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/malattia-di-gaucher/ 2022-05-19T16:58:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/nei-bambini-giovani-adulti-con-lal-recidivata-refrattaria-la-mancata-risposta-al-blinatumomab-e-la-presenza-di-alti-livelli-di-malattia-correlano-con-una-prognosi-peggiore-dopo-trattamento-con-cellule/ 2022-04-27T15:00:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/ponatinib-per-le-fasi-avanzate-nella-lmc-lottimizzazione-del-dosaggio-come-nuova-opzione-terapeutica/ 2022-03-17T09:45:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/asciminib-una-nuova-possibilita-terapeutica-per-la-leucemia-mieloide-cronica/ 2022-03-17T09:41:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-dallamerican-society-of-hematology-ash-congress-2021-su-car-t-nella-leucemia-acuta-linfoblastica-ii/ 2026-04-01T12:51:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-dallamerican-society-of-hematology-ash-congress-2021-sulla-leucemia-acuta-linfoblastica-i/ 2026-04-01T12:51:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/malattia-di-erdheim-chester/ 2022-02-24T16:44:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/malattia-di-rosai-dorfman/ 2022-02-24T13:27:00+00:00 monthly 0.8 https://www.ematologiainprogress.it/video/ 2022-02-17T09:05:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-patologie-benigne-m-d-cappellini/ 2022-09-16T16:45:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-leucemia-mieloide-cronica-m-breccia/ 2022-09-16T16:07:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-leucemia-acuta-mieloide-lam-a-candoni/ 2022-09-16T16:52:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-car-t-a-di-rocco/ 2022-09-16T16:47:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-leucemie-acute-linfoblastiche-lal-s-chiaretti/ 2022-09-16T16:47:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-disordini-mieloproliferativi-cronici-f-passamonti/ 2022-09-16T16:45:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-mieloma-e-zamagni/ 2022-09-16T16:49:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-linfomi-u-vitolo/ 2022-09-16T16:50:39+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-leucemie-linfatiche-croniche-llc-s-molica/ 2022-09-16T16:50:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/dasatinib-e-blinatumomab-per-i-pazienti-adulti-con-leucemia-acuta-linfoblastica-ph-positiva/ 2022-02-15T13:07:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-from-ash-2021-leucemie-acute-mieloidi-lam/ 2026-04-01T12:51:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/follow-up-dei-pazienti-con-lam-r-r-flt3-positiva-trattati-con-gilteritinib-risultati-a-lungo-termine-dello-studio-di-fase-3-admiral/ 2022-02-11T16:46:18+00:00 monthly 0.8 https://www.ematologiainprogress.it/sopravvivenza-a-lungo-termine-in-pazienti-con-lam-70-anni-dopo-chemioterapia-intensiva-o-agenti-ipometilanti-dati-dai-registri-europei/ 2022-02-11T15:45:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/una-migliore-classificazione-molecolare-ottimizza-la-valutazione-del-rischio-in-pazienti-adulti-con-leucemia-acuta-ph-negativa/ 2022-02-11T15:45:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/report-dal-63rd-ash-meeting-patologie-del-ferro/ 2026-04-01T12:51:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfoma-di-hodgkin-dellanziano/ 2022-02-15T13:00:49+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2021-leucemia-linfatica-cronica/ 2026-04-01T12:51:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-dallash2021-sulla-mielofibrosi/ 2026-04-01T12:51:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/cns-involvement-in-aml-at-diagnosis-is-rare-and-does-not-affect-response-or-survival-data-from-11-ecog-acrin-trials/ 2022-02-02T16:03:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-ash-2021-leucemia-mieloide-cronica/ 2026-04-01T12:51:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-sul-mm-dal-congresso-ash-2021/ 2026-04-01T12:51:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2021-sulla-mastocitosi-sistemica/ 2026-04-01T12:51:35+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2021-un-nuovo-farmaco-per-le-neoplasie-mieloidi-linfoidi-con-riarrangiamento-di-fgfr1/ 2026-04-01T12:51:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/best-of-ash-al-63mo-congresso-della-societa-americana-di-ematologia-trial-clinico-randomizzato-gaia/ 2026-04-01T12:51:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/video-registrazioni-dal-5th-international-all-assembly-5-7-novembre-2021/ 2022-01-31T16:53:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/identificazione-genetica-dei-pazienti-con-lam-60-anni-di-eta-che-ottengono-una-sopravvivenza-a-lungo-termine-con-una-chemioterapia-intensiva/ 2022-02-02T16:03:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/venetoclax-e-azacitidina-seguiti-da-trapianto-allogenico-possono-migliorare-la-prognosi-rispetto-alla-terapia-di-mantenimento-nei-pazienti-con-lam-60-anni-di-eta-di-nuova-diagnosi/ 2022-02-02T16:03:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/dinamiche-clonali-ed-implicazioni-cliniche-dellematopoiesi-clonale-post-remissione-nella-lam/ 2022-02-02T16:03:09+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-food-and-drug-administration-fda-ha-approvato-tecartus-brexucabtagene-autoleucel-per-i-pazienti-adulti-con-lal-b-recidivata-refrattaria/ 2022-01-31T16:53:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/webinar-dal-28-ottobre-al-19-novembre-2021-hematology-passport-2-semestre-2021-emostasi-trombosi-ed-highlights-da-altre-patologie/ 2021-10-27T12:03:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/inquadramento-e-trattamento-dei-linfomi-con-localizzazione-al-sistema-nervoso-centrale/ 2021-09-22T15:10:34+00:00 monthly 0.8 https://www.ematologiainprogress.it/impiego-delle-car-t-cells-nel-mieloma-multiplo/ 2021-09-20T15:42:39+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-sulla-terapia-dei-linfomi-non-hodgkin-dal-congresso-eha-2021/ 2022-01-31T16:54:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/i-risultati-del-primo-confronto-diretto-tra-inibitori-della-bruton-tirosin-chinasi-btk-nella-leucemia-linfatica-cronica-recidivata-refrattaria-risultati-ricadute-e-prospettive/ 2022-02-02T16:07:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2021-leucemia-linfatica-cronica-efficacia-e-sicurezza-degli-inibitori-di-btk-e-di-bcl2/ 2022-01-31T16:54:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-in-tema-di-metabolismo-del-ferro-e-patologie-correlate-report-da-eha-2021-virtual-congress/ 2022-01-31T16:55:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/drakesmith-h-et-al-2021/ 2021-07-26T11:32:18+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-sul-mieloma-multiplo-dai-congressi-asco-e-eha-2021/ 2022-01-31T16:55:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/vemurafenib-rituximab-nel-trattamento-della-leucemia-a-cellule-capellute-recidivata-refrattaria/ 2022-02-02T16:07:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/venetoclax-in-combinazione-in-pazienti-con-lam-secondaria-a-mpns-di-nuova-diagnosi-o-recidivata-lesperienza-dellmd-anderson-cancer-center/ 2022-02-02T16:03:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/dal-24-giugno-al-15-luglio-2021-hematology-passport-1-semestre-2021-il-laboratorio-di-ematologia/ 2021-05-10T12:37:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/isatuximab-carfilzomib-e-desametasone-per-il-trattamento-dei-pazienti-affetti-da-mieloma-multiplo-recidivato-e-refrattario/ 2022-01-31T16:56:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuovi-target-e-nuove-terapie-per-il-paziente-affetto-da-mieloma-multiplo-recidivato-e-refrattario-belantamab-mafodotin/ 2022-01-31T16:55:55+00:00 monthly 0.8 https://www.ematologiainprogress.it/llc-un-anno-di-covid-19-in-italia-report-dal-campus-cll-2/ 2021-12-17T12:15:35+00:00 monthly 0.8 https://www.ematologiainprogress.it/llc-un-anno-di-covid-19-in-italia-report-dal-campus-cll/ 2022-01-31T16:56:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/older-adults-with-newly-diagnosed-high-risk-secondary-aml-who-achieved-remission-with-cpx-351-phase-3-post-hoc-analyses/ 2022-02-02T16:03:03+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2020-leucemia-acuta-linfoblasica-escludendo-la-terapia-con-car-t/ 2026-04-01T12:51:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/test/ 2021-03-28T03:00:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/genome-sequencing-as-an-alternative-to-cytogenetic-analysis-in-myeloid-cancers/ 2022-02-02T16:03:00+00:00 monthly 0.8 https://www.ematologiainprogress.it/idecabtagene-vicleucel-nel-trattamento-del-mieloma-multiplo-recidivato-refrattario-risultati-dello-studio-karmma/ 2022-01-31T17:03:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/extra-topic-hematology-passport-terapie-molecolari-per-le-emoglobinopatie-10-marzo-2021/ 2021-03-01T17:51:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2020-selezione-degli-abstracts-piu-rilevanti-in-tema-di-leucemia-mieloide-acuta-lam/ 2026-04-01T12:51:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/piastrinopenia-immune-nella-donna-un-approccio-dedicato/ 2022-02-11T15:55:32+00:00 monthly 0.8 https://www.ematologiainprogress.it/dallash-2020-highlights-sul-linfoma-di-hodgkin/ 2026-04-01T12:51:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-punto-sul-metabolismo-e-sulle-patologie-del-ferro-dal-62-congresso-virtuale-ash-2020/ 2026-04-01T12:51:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-virtual-congress-2020-terapia-con-car-t/ 2026-04-01T12:51:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/linee-guida-italiane-per-il-management-dei-pazienti-con-itp-durante-lemergenza-covid-19-aggiornamento-gennaio-2021/ 2022-02-02T16:38:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/linee-guida-italiane-per-il-management-dei-pazienti-con-itp-durante-lemergenza-covid-19/ 2022-02-02T16:37:49+00:00 monthly 0.8 https://www.ematologiainprogress.it/covid-19-e-neoplasie-mieloproliferative-croniche-risposte-alle-domandi-piu-frequenti/ 2021-04-08T15:50:32+00:00 monthly 0.8 https://www.ematologiainprogress.it/commento-allarticolo-dasatinib-blinatumomab-for-ph-positive-acute-lymphoblastic-leukemia-in-adults-nejm/ 2022-01-31T17:05:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/highligths-dallash-2020-novita-nella-terapia-di-i-linea/ 2026-04-01T12:51:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/prognostic-and-therapeutic-impacts-of-mutant-tp53-variant-allelic-frequency-in-newly-diagnosed-acute-myeloid-leukemia/ 2022-02-02T16:02:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/lisocabtagene-maraleucel-liso-cel-un-nuovo-prodotto-car-t-in-via-di-approvazione/ 2022-02-02T16:06:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/precision-medicine-treatment-in-aml-using-prospective-genomic-profiling-feasibility-and-preliminary-efficacy-of-the-beat-aml-master-trial/ 2022-02-02T16:02:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/impatto-di-gemtuzumab-ozogamicin-su-mrd-e-rischio-di-recidiva-nei-pazienti-con-lam-npm1-mutata-risultati-dello-studio-amlsg-09-09/ 2022-02-02T16:02:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/infezione-da-covid-19-gravita-e-mortalita-nei-pazienti-con-llc-2/ 2020-10-26T09:52:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/infezione-da-covid-19-gravita-e-mortalita-nei-pazienti-con-llc/ 2022-02-02T16:12:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-tempo-dalla-diagnosi-al-trattamento-influisce-sulla-prognosi-dei-pazienti-con-lam-di-nuova-diagnosi/ 2022-02-02T16:02:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/outcomes-of-older-patients-with-npm1-mutated-aml-current-treatments-and-the-promise-of-venetoclax-based-regimens/ 2022-02-02T16:02:55+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-mieloide-acuta-vecchia-bozza-non-usare/ 2023-08-22T14:44:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucaferesi-per-la-gestione-delliperleucocitosi-nella-lam-review-sistematica-e-meta-analisi/ 2022-02-02T16:02:55+00:00 monthly 0.8 https://www.ematologiainprogress.it/azacitidina-orale-per-i-pazienti-con-lam-in-prima-rc/ 2022-02-02T16:15:34+00:00 monthly 0.8 https://www.ematologiainprogress.it/ferro-epcidina-e-infezione-da-coronavirus-2/ 2020-09-07T14:47:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/ferro-epcidina-e-infezione-da-coronavirus/ 2022-02-02T16:15:18+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-cellule-car-t/ 2026-02-19T10:20:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/cellule-car-t-highlights-da-eha-25-2020/ 2022-02-02T16:15:57+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-ruolo-essenziale-di-epcidina-materna-o-fetale-in-gravidanza/ 2022-02-02T16:12:22+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-dal-25-congresso-eha-2020-late-breaking-abstract-e-mieloma-multiplo/ 2022-02-02T16:17:33+00:00 monthly 0.8 https://www.ematologiainprogress.it/effetti-di-basse-o-alte-dosi-di-eparina-a-basso-peso-molecolare-sui-parametri-emostatici-nei-pazienti-critici-con-covid-19-2/ 2020-07-13T11:26:26+00:00 monthly 0.8 https://www.ematologiainprogress.it/effetti-di-basse-o-alte-dosi-di-eparina-a-basso-peso-molecolare-sui-parametri-emostatici-nei-pazienti-critici-con-covid-19/ 2020-07-13T11:24:10+00:00 monthly 0.8 https://www.ematologiainprogress.it/gestione-dei-pazienti-con-llc-e-lmc-durante-la-pandemia-da-covid-19-in-italia-disponibili-online-i-due-articoli-derivati-dalle-survey-dei-campus-cll-e-cml/ 2022-02-02T16:11:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-sul-mieloma-multiplo-da-eha-2020/ 2022-02-02T16:18:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/cll-management-in-italy-during-the-covid-19-pandemic-a-campus-cll-report/ 2020-06-25T17:22:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-sul-mieloma-multiplo-da-asco-2020/ 2022-02-02T16:18:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/covid-19-pandemic-and-cml-a-campus-cml-survey/ 2020-06-25T17:24:42+00:00 monthly 0.8 https://www.ematologiainprogress.it/parametri-emocromocitometrici-e-morfologia-del-sangue-periferico-nei-pazienti-covid-19-2/ 2020-05-14T11:23:19+00:00 monthly 0.8 https://www.ematologiainprogress.it/parametri-emocromocitometrici-e-morfologia-del-sangue-periferico-nei-pazienti-covid-19/ 2022-02-02T16:18:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/aspetti-morfologici-e-immunofenotipici-dei-sottotipi-di-leucemia-acuta-mieloide-in-accordo-con-la-classificazione-who-2016/ 2022-02-02T16:04:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/lal-ph-in-italia-durante-la-pandemia-da-covid-19-lo-studio-del-campus-all/ 2020-05-11T11:31:41+00:00 monthly 0.8 https://www.ematologiainprogress.it/report-del-primo-questionario-effettuato-nellambito-del-campus-cml/ 2020-05-05T10:49:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/covid-19-webinar-series-appuntamenti-settimanali-a-partire-dal-7-maggio-2020/ 2020-05-08T12:46:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/dal-7-maggio-2020-covid-19-webinar-series/ 2020-04-30T16:06:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/11-giugno-2020-ehavirtual/ 2020-04-30T15:50:07+00:00 monthly 0.8 https://www.ematologiainprogress.it/report-del-primo-questionario-effettuato-nellambito-del-campus-cll/ 2020-04-30T18:21:57+00:00 monthly 0.8 https://www.ematologiainprogress.it/trattamento-con-cellule-car-t-nei-linfomi/ 2021-03-05T11:32:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/dasatinib-vs-imatinib-nel-trattamento-della-leucemia-acuta-linfoblastica-ph-del-bambino-risultati-di-uno-studio-multicentrico-randomizzato-di-fase-3/ 2022-02-02T16:11:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/covid-19-e-itp-traduzione-in-italiano-della-guida-sintetica-alla-gestione-dei-pazienti-pubblicata-da-ash/ 2026-04-01T12:51:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/covid-19-e-itp-traduzione-in-italiano-della-guida-sintetica-alla-gestione-dei-pazienti-pubblicata-da-ash-2/ 2026-04-01T12:51:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/dallash-2019-highlights-sui-disordini-istiocitari/ 2026-04-01T12:51:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/aml-and-covid-19-pandemic/ 2020-05-08T12:49:33+00:00 monthly 0.8 https://www.ematologiainprogress.it/report-del-primo-questionario-effettuato-nellambito-del-campus-all/ 2020-05-04T12:46:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-covid19-crisis/ 2020-05-08T12:51:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/ash-covid19-resources/ 2026-04-01T12:51:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/covid-19-e-neoplasie-mieloproliferative-croniche-mpn-considerazioni-di-un-gruppo-di-esperti-della-societa-americana-di-ematologia-ash/ 2026-04-01T12:51:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/video-in-arrivo-online/ 2020-03-30T16:43:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/approfondimento-in-arrivo-online/ 2020-03-30T16:44:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/emergenza-covid-19/ 2021-10-04T13:17:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/potentially-highly-potent-drugs-for-2019-ncov/ 2020-03-30T18:06:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/uso-delle-cellule-natural-killer-trasdotte-con-recettore-car-nelle-patologie-linfoproliferative-cd19-positive/ 2022-02-02T16:00:13+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamenti-sullimmunoterapia-nel-mieloma-multiplo/ 2020-02-19T17:06:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/dallash-2019-car-t-cell-nella-leucemia-acuta-linfoblastica/ 2026-04-01T12:51:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/ladattamento-allipossia-un-processo-biologico-da-nobel/ 2022-02-02T16:23:23+00:00 monthly 0.8 https://www.ematologiainprogress.it/dallash-2019-highlights-sul-linfoma-di-hodgkin/ 2026-04-01T12:51:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/dallash-2019-highlights-sulla-llc/ 2026-04-01T12:51:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-swg-scientific-meeting-on-mesenchymal-stromal-cells-and-tissue-homeostasis/ 2020-01-16T17:20:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/asciminib-nuovo-inibitore-tirosin-chinasico-per-i-pazienti-affetti-da-leucemia-mieloide-cronica/ 2022-02-02T16:10:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/who-2017-ed-eosinofilia/ 2021-02-08T12:33:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamenti-sulla-morfologia/ 2021-02-08T12:36:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/dallash-2019-dasatinib-blinatumomab-per-la-lal-ph-risultati-dello-studio-d-alba/ 2026-04-01T12:51:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/dallash-2019-quazar-aml-001-risultati-iniziali-di-un-trial-internazionale-di-fase-iii-randomizzato-in-doppio-cieco-di-cc-486-formulazione-orale-di-azacitidina-vs-placebo-in-pazienti-co/ 2026-04-01T12:51:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dallash-2019/ 2026-04-01T12:51:03+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamenti-sulla-nomenclatura-di-condizioni-associate-a-emopoiesi-clonale/ 2019-12-13T11:22:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/30-31-marzo-2020-milano-italia-terapie-personalizzate-nelle-neoplasie-mieloidi/ 2020-02-20T10:53:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/22-25-marzo-2020-madrid-spagna-46-annual-meeting-dellebmt/ 2020-02-20T10:59:13+00:00 monthly 0.8 https://www.ematologiainprogress.it/22-22-marzo-2020-parigi-francia-1st-translational-research-conference-on-chronic-lymphocytic-leukaemia/ 2020-02-20T10:58:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/19-20-marzo-2020-alessandria-italia-emorragie-e-trombosi-in-corso-di-neoplasie-ematologiche/ 2020-02-20T10:58:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/13-15-febbraio-2020-napoli-italia-post-orlando-2019/ 2020-01-13T17:16:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-mieloide-acuta-flt3-recidivata-refrattaria-gilteritinib-vs-chemioterapia-risultati-dello-studio-admiral/ 2022-02-02T16:25:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-presenza-di-minimal-residual-disease-dopo-trapianto-allogenico-predice-la-recidiva-precoce-nelle-lam-npm1-positive/ 2022-02-02T16:02:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/outcome-del-trapianto-allogenico-in-2-rc-per-le-core-binding-factor-lam/ 2022-02-02T16:02:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/commento-allo-studio-ascend-ace-cl-309/ 2022-02-02T16:26:10+00:00 monthly 0.8 https://www.ematologiainprogress.it/30-gennaio-1-febbraio-2020-sitges-barcellona-2nd-european-car-t-cell-meeting/ 2020-01-13T17:13:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/16-dicembre-2019-roma-stato-dellarte-e-nuovi-orizzonti-terapeutici-nel-trattamento-dei-linfomi/ 2019-11-27T16:14:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/7-10-dicembre-2019-orlando-fl-61-ash-annual-meeting-2019-call-for-abstract/ 2026-04-01T12:51:03+00:00 monthly 0.8 https://www.ematologiainprogress.it/14-16-novembre-2019-rimini-riunione-nazionale-fil/ 2020-01-13T17:13:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/e-partito-il-progetto-hematology-passport-2019-2022/ 2019-09-23T14:17:07+00:00 monthly 0.8 https://www.ematologiainprogress.it/fattori-associati-ad-una-event-free-survival-durevole-in-pazienti-affetti-da-leucemia-linfoblastica-acuta-a-fenotipo-b-con-malattia-minima-residua-negativa-dopo-trattamento-con-cellule-car-t-anti-cd19/ 2022-02-02T16:00:13+00:00 monthly 0.8 https://www.ematologiainprogress.it/bando-under-40-in-hematology-2019/ 2020-01-13T17:13:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/outcome-del-trapianto-aploidentico-vs-donatore-familiare-compatibile-per-la-lam-in-prima-rc/ 2022-02-02T16:02:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-from-eha-2019-novita-sul-metabolismo-del-ferro/ 2022-02-02T16:26:55+00:00 monthly 0.8 https://www.ematologiainprogress.it/24-26-ottobre-2019-estoril-portogallo-5th-international-conference-acute-myeloid-leukemia/ 2019-07-09T16:54:01+00:00 monthly 0.8 https://www.ematologiainprogress.it/widget/ 2021-10-04T13:25:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/13-15-ottobre-2019-catania-xliv-congresso-nazionale-aieop/ 2019-05-09T17:12:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/13-15-ottobre-2019-catania-xliv-congresso-nazionale-aieop-2/ 2019-05-09T17:17:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/trattamento-con-inotuzumab-ozogamcin-in-pazienti-pediatrici-con-leucemia-acuta-linfoblastica-recidivata-refrattaria/ 2022-02-02T16:00:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuovi-meccanismi-di-resistenza-nella-lal-t-del-bambino/ 2022-02-02T16:00:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/2-4-ottobre-2019-glasgow-uk-ecth-2019/ 2019-04-03T17:02:09+00:00 monthly 0.8 https://www.ematologiainprogress.it/ixazomib-lenalidomide-e-desametasone-per-il-paziente-affetto-da-mieloma-multiplo-recidivato-e-o-refrattario/ 2022-02-02T16:28:01+00:00 monthly 0.8 https://www.ematologiainprogress.it/6-8-settembre-2019-genova-10-bic-international-conference/ 2019-03-06T17:50:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/13-16-giugno-2019-amsterdam-olanda-24th-eha-annual-congress/ 2019-04-03T17:06:57+00:00 monthly 0.8 https://www.ematologiainprogress.it/13-14-maggio-2019-bologna-aggressive-lymphoma-workshop/ 2019-03-06T17:53:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/metabolismo-del-ferro-e-disordini-correlati-review-series/ 2022-02-02T16:28:39+00:00 monthly 0.8 https://www.ematologiainprogress.it/5-7-aprile-2019-berlino-2nd-how-to-diagnose-and-treat-multiple-myeloma-2/ 2019-03-06T17:50:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/4-5-aprile-2019-vienna-leukemia-2019/ 2019-03-06T17:51:01+00:00 monthly 0.8 https://www.ematologiainprogress.it/ash-2018-aggiornamento-sul-trattamento-del-linfoma-di-hodgkin/ 2026-04-01T12:50:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/venetoclax-combinato-con-decitabina-o-azacitidina-nei-pazienti-anziani-non-pretrattati-con-lam/ 2022-02-02T16:02:03+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-mantenimento-con-azacitidina-dopo-chemioterapia-intensiva-migliora-la-dfs-nei-pazienti-anziani-con-lam/ 2022-02-02T16:02:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-leucemia-acuta-linfoblastica-opuscolo-per-il-paziente/ 2022-02-02T16:29:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-from-ash-2018-san-diego-highlights-sul-mieloma-multiplo-2/ 2026-04-01T12:50:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-commissione-europea-approva-la-combinazione-venetoclax-piu-rituximab-per-il-trattamento-di-pazienti-con-llc-che-hanno-ricevuto-almeno-una-terapia-precedente/ 2022-02-02T16:29:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-from-ash-2018-san-diego-la-malattia-di-castleman/ 2026-04-01T12:50:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-from-ash-2018-san-diego-metabolismo-del-ferro/ 2026-04-01T12:50:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-from-ash-2018-san-diego-highlights-sul-mieloma-multiplo/ 2026-04-01T12:50:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/polatuzumab-vedotin-in-associazione-a-rituximab-o-obinutuzumab-piu-bendamustina-nel-linfoma-diffuso-a-grandi-cellule-b-recidivati-o-refrattario-risultati-aggiornati-dello-studio-di-fase-ib-ii/ 2018-12-19T18:55:03+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-from-ash-2018-san-diego-aggiornamenti-sulla-terapia-dei-linfomi-non-hodgkin/ 2026-04-01T12:50:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/approvazione-fda-di-gilteritinib-per-la-lam-recidivata-o-refrattaria-con-mutazione-di-flt3/ 2022-02-02T16:30:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/up-date-su-istiocitosi-a-cellule-di-langerhans-e-malattia-di-erdheim-chester-dal-34-meeting-dellhystiocyte-society/ 2022-02-02T16:31:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-from-ash-2018-san-diego-novita-sulle-leucemie-acute-mieloidi/ 2026-04-01T12:50:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-from-ash-2018-san-diego-novita-biologiche-sulle-neoplasie-mieloproliferative-croniche-mastocitosi/ 2026-04-01T12:50:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-from-ash-2018-san-diego-novita-biologiche-sulle-neoplasie-mieloproliferative-croniche-la-mutazione-calr/ 2026-04-01T12:50:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-from-ash-2018-san-diego-novita-biologiche-sulle-neoplasie-mieloproliferative-croniche/ 2026-04-01T12:50:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-from-ash-2018-san-diego-la-sessione-educazionale-sulle-neoplasie-mieloproliferative-croniche/ 2026-04-01T12:50:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/inotuzumab-e-chemioterapia-non-intensiva-seguiti-o-meno-da-blinatumomab-come-terapia-per-pazienti-affetti-da-lal-ph-in-prima-recidiva/ 2022-02-02T16:00:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-bcr-abl1-like-predictor-un-saggio-rapido-ed-economico-per-lidentificazione-dei-casi-bcr-abl1-like-alla-diagnosi-di-malattia/ 2022-02-02T16:00:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/take-me-home-in-ematologia-angelo-vacca-e-daniele-derudas/ 2018-11-26T16:06:22+00:00 monthly 0.8 https://www.ematologiainprogress.it/trattamento-chemio-free-con-lenalidomide-e-rituximab-come-prima-linea-dei-pazienti-con-linfoma-follicolare-avanzato/ 2022-02-02T15:58:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/ibrutinib-e-venetoclax-nel-trattamento-del-linfoma-mantellare-ricaduto-refrattario-2/ 2022-02-02T15:58:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/24-27-marzo-2019-francoforte-45th-annual-meeting-of-the-ebmt/ 2018-10-30T15:34:49+00:00 monthly 0.8 https://www.ematologiainprogress.it/14-16-febbraio-2019-parigi-1st-european-car-t-cell-meeting/ 2019-02-04T16:24:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/60-ash-meeting-2018/ 2026-04-01T12:50:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-linfoblastica-acuta-video-intervista-al-prof-robin-foa/ 2018-11-05T12:20:18+00:00 monthly 0.8 https://www.ematologiainprogress.it/12-13-novembre-2018-riccione-giornate-aieop-2018/ 2018-10-30T15:26:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/venetoclax-e-rituximab-nella-llc-recidivata-o-refrattaria-commenti-della-comunita-scientifica/ 2018-10-02T10:02:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/take-me-home-in-ematologia-mario-boccadoro-e-maria-teresa-petrucci/ 2018-10-25T15:36:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/obinotuzumab-in-the-treatment-of-chronic-lymphocytic-leukemia/ 2022-02-02T15:56:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/24-26-ottobre-2018-marsiglia-ecth-2018/ 2018-09-10T13:13:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/the-young-side-of-lymphoma/ 2018-09-10T13:14:01+00:00 monthly 0.8 https://www.ematologiainprogress.it/20-21-settembre-2018-udine-il-trapianto-allogenico-nei-linfomi-e-nel-mm/ 2018-09-05T15:50:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/e-oggi-possibile-prevedere-nei-soggetti-anziani-linsorgenza-di-leucemia-mieloide-acuta/ 2022-02-02T15:53:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/phase-iii-randomized-study-of-cpx-351-liposome-for-injection-in-older-patients-with-newly-diagnosed-secondary-acute-myeloid-leukemia/ 2022-02-02T15:53:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/12-14-ottobre-2018-varsavia-eha-swg-scientific-meeting-on-aging-and-hematology/ 2018-09-03T16:53:48+00:00 monthly 0.8 https://www.ematologiainprogress.it/take-me-home-in-ematologia-robin-foa-e-paola-minetto/ 2018-09-21T11:52:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/varianti-germinali-di-ikzf1-predispongono-allo-sviluppo-della-lal-nei-bambini/ 2022-02-02T15:55:55+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuove-alterazioni-genetiche-nella-lal-b/ 2018-07-11T13:30:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/quale-ruolo-per-la-splenectomia-nellitp-cronica-degli-adulti-unanalisi-dettagliata-delle-evidenze/ 2018-07-06T17:35:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/clearance_of_somatic_mutations_at_remission_and_the_risk_of_relapse_in_aml/ 2022-02-02T15:53:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/prospective-randomized_comparison_of_idarubicin/ 2022-02-02T15:53:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/aplasia-midollare-acquisita/ 2022-02-02T15:26:28+00:00 monthly 0.8 https://www.ematologiainprogress.it/challenges-in-lectio-magistralis-ph-and-ph-like-all-hagop-m-kantarjian/ 2018-07-24T13:45:07+00:00 monthly 0.8 https://www.ematologiainprogress.it/challenges-in-management-of-ph-all-today-sabina-chiaretti/ 2018-07-26T12:58:07+00:00 monthly 0.8 https://www.ematologiainprogress.it/challenges-in-management-of-ph-all-and-cml-today-elias-jabbour/ 2018-07-24T13:46:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/challenges-in-management-of-cml-today-massimo-breccia/ 2018-07-26T12:56:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/cll-conference-2017-intervista-a-susan-obrien/ 2018-07-24T13:52:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/cll-conference-2017-intervista-a-jan-burger/ 2018-07-24T13:52:20+00:00 monthly 0.8 https://www.ematologiainprogress.it/challenges-in-management-of-ph-leukemias-today-2018/ 2018-06-26T11:43:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/molecular-minimal-residual-disease-in-acute-myeloid-leukemia/ 2022-02-02T15:53:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/17-21-luglio-2018-dublino-isth-ssc-2018/ 2018-06-01T17:59:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/6-luglio-2018-ferrara-attualita-in-ematologia-isth-ssc-2018/ 2018-06-01T17:58:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/cookie-policy/ 2021-10-04T13:17:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/privacy-policy/ 2021-10-04T13:21:21+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-malattia-minima-residua-mrd-nel-mieloma-multiplo/ 2018-05-17T17:18:28+00:00 monthly 0.8 https://www.ematologiainprogress.it/erythrocytic-ferroportin-reduces-intracellular-iron-accumulation-hemolysis-and-malaria-risk/ 2022-02-02T15:56:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/campus-all/ 2018-03-28T10:18:35+00:00 monthly 0.8 https://www.ematologiainprogress.it/termini-e-condizioni/ 2021-10-04T13:24:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/stereotipia-recettoriale/ 2018-03-23T17:51:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-cariotipo-complesso-nella-llc/ 2018-03-23T17:49:55+00:00 monthly 0.8 https://www.ematologiainprogress.it/anti-cd19-car-t-cells-nella-leucemia-acuta-linfoblastica-primo-follow-up-a-lungo-termine/ 2022-02-02T15:55:55+00:00 monthly 0.8 https://www.ematologiainprogress.it/daratumumab-nei-pazienti-con-mm-di-nuova-diagnosi-risultati-ad-interim-dello-studio-alcyone/ 2018-03-09T13:21:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/take-me-home-in-ematologia-giovanni-pizzolo-e-annalisa-chiarenza-2/ 2018-08-09T12:04:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-cliniche-dallash-2017-neoplasie-mieloproliferative-croniche/ 2026-04-01T12:50:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/terapia-di-mantenimento-con-rituximab-nei-linfomi-non-hodgkin-b/ 2018-02-08T17:26:32+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-profilo-bcr-abl1-like-e-associato-a-prognosi-sfavorevole-anche-nei-protocolli-guidati-dalla-malattia-minima-residua-risultati-del-protocollo-pediatrico-anzchog-all8/ 2022-02-02T15:55:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/lal-bcr-abl1-like/ 2018-02-16T17:21:14+00:00 monthly 0.8 https://www.ematologiainprogress.it/patient-day-leucemia-linfatica-cronica/ 2018-08-09T11:54:34+00:00 monthly 0.8 https://www.ematologiainprogress.it/inotuzumab-e-chemioterapia-non-intensiva-come-terapia-di-prima-linea-per-pazienti-anziani-con-leucemia-acuta-linfoblastica-lal-ph/ 2022-02-02T15:55:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/14-17-giugno-2018-stoccolma-23rd-eha-annual-congress-call-for-abstract/ 2018-02-05T11:35:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/anti-cd22-car-t-cells-nuovi-target-per-la-terapia-cellulare/ 2022-02-02T15:55:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/bologna-28-29-maggio-2018-xliii-congresso-nazionale-aieop-call-for-abstract/ 2018-02-05T11:35:48+00:00 monthly 0.8 https://www.ematologiainprogress.it/leukemia-2018/ 2018-01-26T10:23:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/14-15-maggio-2018-bologna-riunione-nazionale-gitmo-2018/ 2018-03-16T11:10:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/4-6-maggio-2018-budapest-ungheria-clinical-updates-acute-leukemias/ 2018-01-26T10:23:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/approfondimenti/ 2021-10-04T13:17:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/19-21-aprile-2018-torino-1st-european-myeloma-network-meeting/ 2018-02-16T13:14:23+00:00 monthly 0.8 https://www.ematologiainprogress.it/12-14-aprile-2018-barcellona-new-molecular-insights-and-innovative-management-approaches-for-all/ 2018-01-26T15:19:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-terapia-linfociti-t-portatori-recettori-chimerici-lantigene-car-t-cells-nei-linfomi-non-hodgkin/ 2022-02-02T15:55:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuovi-farmaci-registrati-nel-2017-la-terapia-della-leucemia-mieloide-acuta/ 2018-01-09T16:11:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/mieloma-multiplo-highlights-dallash/ 2026-04-01T12:50:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/cll-conference-2017-intervista-a-carlo-m-croce/ 2018-07-24T13:52:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-mieloide-acuta-novita-dallash-2017/ 2026-04-01T12:50:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/4th-international-conference-hematologic-malignancies-at-older-age/ 2017-11-15T13:05:13+00:00 monthly 0.8 https://www.ematologiainprogress.it/clinical-updates-cll-and-indolent-lymphoma/ 2017-11-15T13:05:26+00:00 monthly 0.8 https://www.ematologiainprogress.it/59-ash-annual-meeting/ 2026-04-01T12:50:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuove-prospettive-nel-campo-della-leucemia-acuta-mieloide-francesco-lo-coco/ 2017-10-17T12:21:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/salute-del-sangue-2017/ 2017-10-04T09:57:19+00:00 monthly 0.8 https://www.ematologiainprogress.it/tragedia-perseveranza-fortuna-la-storia-delle-car-t/ 2017-10-04T10:37:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/46-congresso-nazionale-sie-2017/ 2017-11-15T13:05:42+00:00 monthly 0.8 https://www.ematologiainprogress.it/approvazione-delle-car-t-nelle-leucemie-acute-linfoblastiche-b/ 2017-10-26T17:22:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfomi-mantellari-eha-2017-carlo-visco/ 2017-10-04T10:29:55+00:00 monthly 0.8 https://www.ematologiainprogress.it/llc-seminario-pazienti-medici/ 2017-11-15T13:07:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/highlights-dalleha-2017-long-term-follow-dello-studio-eloquent-2-elotuzumab-lenalidomide-desametasone-versus-lenalidomide-desametasone/ 2017-09-08T17:01:02+00:00 monthly 0.8 https://www.ematologiainprogress.it/ash-meeting-2017-call-for-abstract/ 2026-04-01T12:50:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/glossary-2/ 2021-10-04T13:17:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-views-2-3/ 2021-10-04T13:23:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/bic-international-conference/ 2017-05-18T17:07:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-views-2-2/ 2021-10-04T13:17:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/angiocrine-bmp2-signaling-murine-liver-controls-normal-iron-homeostasis/ 2022-02-02T15:54:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/blinatumomab-versus-chemotherapy-for-advanced-acute-lymphoblastic-leukemia/ 2022-02-02T15:54:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/long-term-outcome-of-apl-treated-with-all-trans-retinoic-acid-arsenic-trioxide-and-gemtuzumab/ 2022-02-02T15:53:40+00:00 monthly 0.8 https://www.ematologiainprogress.it/ruolo-brentuximab-vedotin-nella-terapia-del-linfoma-hodgkin-pier-luigi-zinzani/ 2017-03-28T11:48:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/scelti-per-voi/ 2024-01-19T15:20:41+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-views/ 2021-10-04T13:20:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-malattie-rare/ 2022-02-02T15:30:10+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-metabolismo-ferro/ 2026-03-16T14:07:40+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-piastrinopenia-immune/ 2025-07-28T14:55:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-infezioni-pazienti-ematologici/ 2021-10-04T13:19:42+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-leucemia-acuta-linfoide/ 2022-02-02T14:48:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-leucemia-linfatica-cronica/ 2022-07-21T14:30:22+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-leucemia-mieloide-acuta/ 2023-08-22T12:45:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-leucemia-mieloide-cronica/ 2022-02-02T16:42:48+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-linfoma-di-hodgkin/ 2024-04-08T11:09:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-linfoma-non-hodgkin/ 2024-04-08T11:09:40+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-mieloma-multiplo/ 2025-10-06T11:09:33+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-piattaforme-diagnosi-ematologia/ 2022-02-02T16:20:21+00:00 monthly 0.8 https://www.ematologiainprogress.it/sez-sindromi-mieloprofilerative-croniche/ 2026-01-12T12:36:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/pagina-di-registrazione/ 2021-10-04T13:21:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/prova-2/ 2021-10-04T13:24:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/selezione-degli-abstract-piu-rilevanti-presentati-allash-2016-sulla-leucemia-mieloide-acuta/ 2026-04-01T12:50:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/template-sezioni/ 2021-10-04T13:24:39+00:00 monthly 0.8 https://www.ematologiainprogress.it/random/ 2021-10-04T13:22:40+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuovi-farmaci-in-ematologia-oncologica/ 2017-03-16T16:49:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfoma-di-hodgkin-e-terapia-dei-checkpoint-immunitari/ 2018-02-15T17:01:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/ 2026-04-01T12:55:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/account/ 2021-10-04T13:13:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/password-reset/ 2021-10-04T13:21:10+00:00 monthly 0.8 https://www.ematologiainprogress.it/user/ 2022-03-14T11:26:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/login/ 2021-10-04T13:20:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/register/ 2021-10-04T13:22:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/members/ 2021-10-04T13:20:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/logout/ 2021-10-04T13:20:48+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamenti-dallash-2016-sulla-terapia-dei-linfomi-non-hodgkin/ 2026-04-01T12:50:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/ix-international-florence-meeting-on-hematology-target-therapy/ 2017-03-15T12:35:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/application-del-myeloma-frailty-score/ 2017-03-08T12:37:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/9-congresso-nazionale-siica/ 2017-02-16T09:59:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/intervista-al-prof-foa-aspetti-importanti-e-nuove-prospettive-nel-campo-della-leucemia-linfoblastica-acuta/ 2017-05-16T14:13:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/intervista-alla-prof-ssa-fiorina-giona-malattie-rare/ 2020-03-30T16:18:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamenti-dallash-2016-terapia-della-leucemia-linfatica-cronica-llc/ 2026-04-01T12:50:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/dallash-2016-ferro-non-solo-eritropoiesi/ 2026-04-01T12:42:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/hematologic-diseases-in-the-elderly/ 2017-03-16T16:47:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/mieloma-a-catene-leggere-valutazione-sul-siero-e-non-sulle-urine/ 2018-03-09T13:16:13+00:00 monthly 0.8 https://www.ematologiainprogress.it/ebmt-2017/ 2017-02-13T15:22:01+00:00 monthly 0.8 https://www.ematologiainprogress.it/22nd-congress-of-eha-abstract-deadline/ 2017-02-13T15:22:20+00:00 monthly 0.8 https://www.ematologiainprogress.it/molte-luci-e-poche-ombre-sullimpiego-di-ibrutinib-nella-pratica-clinica/ 2022-02-02T15:54:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/international-conference-on-lymphoid-malignancies/ 2017-02-13T15:23:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/tp53-and-decitabine-in-acute-myeloid-leukemia-and-myelodysplastic-syndromes/ 2022-02-02T15:53:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/58th-ash-annual-meeting/ 2026-04-01T12:42:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/strategie-di-approccio-tra-la-patologia-ematologica-acuta-e-cronica-qual-e-il-vero-need/ 2017-05-16T14:48:57+00:00 monthly 0.8 https://www.ematologiainprogress.it/the-genomic-landscape-of-core-binding-factor-acute-myeloid-leukemias/ 2022-02-02T15:53:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/xiii-congresso-nazionale-fimua/ 2016-11-15T16:15:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/emopatie-non-maligne-e-trapianto/ 2017-02-13T15:24:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/training-course-on-who-classification/ 2017-02-13T15:24:07+00:00 monthly 0.8 https://www.ematologiainprogress.it/grandangolo-in-ematologia-2016/ 2016-10-03T15:50:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/innovative-therapies-for-lymphoid-malignancies/ 2016-10-26T15:31:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/miglior-outcome-con-laggiunta-di-rituximab-nelle-lal/ 2018-03-09T13:16:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/xiv-congresso-nazionale-sies/ 2016-09-06T14:42:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/vii-edizione-giornate-ematologiche-vicentine/ 2016-09-12T15:57:22+00:00 monthly 0.8 https://www.ematologiainprogress.it/forum-in-ematologia/ 2016-09-12T12:34:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/in-progress/ 2022-09-20T13:03:00+00:00 monthly 0.8 https://www.ematologiainprogress.it/debates-and-controversies-in-hematology/ 2016-07-15T14:52:35+00:00 monthly 0.8 https://www.ematologiainprogress.it/2nd-international-conference-on-new-concepts-in-b-cell-malignancies/ 2016-09-12T15:58:14+00:00 monthly 0.8 https://www.ematologiainprogress.it/understanding-and-treating-chronic-myeloid-neoplasms/ 2016-07-15T14:56:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-21-copenhagen-9-12-giugno-2016-selezione-degli-abstract-piu-rilevanti-in-tema-di-leucemie-acute/ 2017-05-17T14:55:07+00:00 monthly 0.8 https://www.ematologiainprogress.it/classificazione-genomica-e-prognosi-nella-leucemia-mieloide-acuta/ 2022-02-02T15:53:34+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamenti-nella-diagnostica-morfologica-delle-sindromi-mielodisplastiche/ 2022-02-02T16:04:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/mini-epcidine-per-il-trattamento-della-beta-talassemia-e-della-policitemia-vera/ 2022-02-01T17:41:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/21mo-eha-congress/ 2018-03-09T13:16:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-rohs-rsh-tutorial-on-managing-complications-in-hematologic-patients/ 2016-04-15T16:49:03+00:00 monthly 0.8 https://www.ematologiainprogress.it/registrazione-mailup/ 2021-10-04T13:22:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/emofilia-a-frequenza-di-inibitori-e-nuovi-trattamenti/ 2018-03-09T13:16:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/21-eha-annual-meeting-abstract-submission/ 2016-09-12T15:59:22+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-leucemia-mieloide-acuta-a-localizzazione-extra-midollare-e-lam/ 2017-05-15T15:50:41+00:00 monthly 0.8 https://www.ematologiainprogress.it/un-passo-avanti-nella-comprensione-delle-fasi-inziali-della-patogenesi-della-leucemia-linfatica-cronica/ 2022-02-01T17:42:35+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuovo-aumento-degli-accessi-al-sito/ 2016-04-20T13:09:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/malattie-rare-al-policlinico-umberto-i/ 2016-04-15T16:51:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-primo-trattato-on-line-ad-aggiornamento-continuo/ 2016-06-17T14:22:18+00:00 monthly 0.8 https://www.ematologiainprogress.it/sponsor/ 2016-04-15T16:40:40+00:00 monthly 0.8 https://www.ematologiainprogress.it/minimal-residual-disease-in-onco-hematology/ 2016-04-15T16:51:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/genetica-molecolare-delle-leucemie-mieloidi-acute/ 2018-02-16T17:00:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/ebmt-2016/ 2016-04-15T16:51:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/revolution-on-thrombocytopenia-management/ 2016-04-15T16:51:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/assessment-della-malattia-minima-residua-mrd-nelle-leucemie-mieloidi-acute-lam-a-rischio-standard/ 2022-02-01T17:43:18+00:00 monthly 0.8 https://www.ematologiainprogress.it/masterclass-sui-nuovi-farmaci-in-ematologia-oncologica/ 2016-04-15T17:07:34+00:00 monthly 0.8 https://www.ematologiainprogress.it/personalized-treatment-in-lymphoid-tumors/ 2016-04-15T17:07:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/farmaci-target-della-via-di-segnalazione-del-b-cell-receptor-nei-linfomi/ 2017-03-21T14:18:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/57-congresso-dellamerican-society-of-hematology-aggiornamenti-sulla-mastocitosi/ 2017-05-16T15:46:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/fiorina-giona/ 2016-02-04T11:43:48+00:00 monthly 0.8 https://www.ematologiainprogress.it/meet-the-expert-treatment-of-aml/ 2017-05-16T15:47:28+00:00 monthly 0.8 https://www.ematologiainprogress.it/trattamento-della-sideropenia-sappiamo-veramente-come-utilizzare-la-terapia-con-ferro-orale/ 2022-02-01T17:41:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/basic-immunology-di-piero-musiani-e-guido-forni/ 2016-04-15T17:10:14+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamento-dallash-ulteriori-importanti-progressi-nella-terapia-della-llc/ 2026-04-01T12:42:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-dallash-2015-abstracts-piu-rilevanti-sulla-lam/ 2026-04-01T12:42:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/anomalie-cromosomiche-nel-mieloma-multiplo-non-tutte-le-trisomie-sono-uguali/ 2016-04-15T17:10:23+00:00 monthly 0.8 https://www.ematologiainprogress.it/dalla-plenary-dellash-best-abstracts-da-orlando/ 2026-04-01T12:42:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuovi-orizzonti-nel-linfoma-follicolare-e-llc/ 2015-11-27T15:55:42+00:00 monthly 0.8 https://www.ematologiainprogress.it/ebmt-2016-call-for-abstract/ 2015-11-27T17:00:18+00:00 monthly 0.8 https://www.ematologiainprogress.it/57th-ash-annual-meeting-exposition/ 2016-04-15T17:20:21+00:00 monthly 0.8 https://www.ematologiainprogress.it/1-giornata-epidemiologica-della-difesa/ 2015-11-27T16:41:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/atti-45-congresso-sie-2015/ 2017-05-18T09:44:09+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamenti-in-aferesi-produttiva/ 2016-04-15T17:20:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/brentuximab-vedotin-nei-linfomi-anaplastici-a-cellule-t/ 2017-05-18T09:44:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/trattamento-del-linfoma-b-primitivo-del-mediastino/ 2017-05-18T09:44:42+00:00 monthly 0.8 https://www.ematologiainprogress.it/rituximab-nei-linfomi-a-cellule-b/ 2017-05-18T09:43:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/aspettando-lash/ 2026-04-01T12:42:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/grandangolo-in-ematologia-2015/ 2015-10-08T13:54:48+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuove-frontiere-in-oncoematologia/ 2015-09-29T13:57:55+00:00 monthly 0.8 https://www.ematologiainprogress.it/ibrutinib-nella-llc-due-facce-della-stessa-medaglia/ 2016-04-15T17:10:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/epidemiologia-e-prognosi-delle-lam-secondarie/ 2022-02-01T17:43:18+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfoma-di-hodgkin-in-corso-di-gravidanza/ 2017-05-16T16:08:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/workshop-ematologia-traslazionale/ 2015-10-08T13:52:01+00:00 monthly 0.8 https://www.ematologiainprogress.it/meeting-leukemia-predisposing-genes/ 2015-09-23T16:01:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/acido-all-trans-retinoico-atra-e-triossido-di-arsenico-ato-per-la-terapia-della-lap-in-ogni-gruppo-di-rischio-risultati-del-trial-randomizzato-aml-17/ 2022-02-01T17:43:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/45-congresso-nazionale-sie/ 2015-06-22T17:24:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/diamo-un-po-di-numeri/ 2015-09-29T14:31:34+00:00 monthly 0.8 https://www.ematologiainprogress.it/una-miniera-di-dati-sul-genoma-della-llc/ 2022-02-01T17:42:32+00:00 monthly 0.8 https://www.ematologiainprogress.it/non-utilita-dello-screening-ct-per-tumori-nel-tev/ 2015-09-24T12:31:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/15th-international-myeloma-workshop/ 2015-05-14T17:11:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/omeostasi-del-ferro-nelle-infezioni-e-nellinfiammazione/ 2022-02-01T17:41:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/un-nuovo-modello-di-regolazione-del-livello-della-trombopoietina/ 2022-02-01T17:40:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/una-pietra-tombale-sul-rituximab-pre-splenectomia-nellitp-risultati-del-ript-trial/ 2022-02-01T17:40:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-mieloide-acuta-novita-dalleha-2015/ 2017-05-16T16:23:34+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamenti-dal-congresso-della-european-hematology-association-eha-leucemia-linfatica-cronica/ 2017-05-16T16:23:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/aggiornamento-dei-dati-di-pfe-e-os-dello-studio-cll11/ 2022-02-01T17:40:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/57-ash-meeting-2015-call-for-abstract/ 2026-04-01T12:42:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/associazione-atraato-e-leucemia-acuta-mieloide-con-mutazione-npm1/ 2022-02-01T17:39:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-paradosso-di-simpson-e-limpatto-delle-mutazioni-di-dnmt3a-nella-lam/ 2022-02-01T17:39:41+00:00 monthly 0.8 https://www.ematologiainprogress.it/20th-congress-of-eha/ 2015-04-24T15:02:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/anemia-da-carenza-di-ferro-un-problema-globale/ 2015-06-10T13:54:41+00:00 monthly 0.8 https://www.ematologiainprogress.it/borsa-di-studio-associazione-cristina-bassi-2015/ 2015-04-24T15:09:13+00:00 monthly 0.8 https://www.ematologiainprogress.it/terapia-di-salvataggio-dopo-recidiva-di-lam/ 2022-02-01T17:39:37+00:00 monthly 0.8 https://www.ematologiainprogress.it/infezioni-virali-nel-paziente-trapiantato/ 2015-05-14T17:12:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-swg-meeting-focus-on-aging-and-hematology-2/ 2015-04-24T15:03:39+00:00 monthly 0.8 https://www.ematologiainprogress.it/hematology-academy-2015/ 2015-04-24T15:14:19+00:00 monthly 0.8 https://www.ematologiainprogress.it/trattamento-pet-guidato-nel-linfoma-di-hodgkin-in-stadio-iniziale/ 2015-04-27T17:11:39+00:00 monthly 0.8 https://www.ematologiainprogress.it/t-cell-lymphomas-we-are-illuminating-the-darkest-of-tunnels/ 2015-04-24T15:04:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/confronto-fra-60-e-90-mgmq-di-daunorubicina-nellinduzione-della-lam-risultati-dello-studio-uk-ncri-aml17/ 2022-02-01T17:38:09+00:00 monthly 0.8 https://www.ematologiainprogress.it/axitinib-inibisce-efficacemente-bcr-abl1t315i-con-una-conformazione-di-legame-distinta/ 2022-02-01T17:37:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfociti-car-e-applicazioni-terapeutiche/ 2021-09-16T09:53:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/pd-1-blockade-with-nivolumab-in-relapsed-or-refractory-hodgkins-lymphoma-2/ 2022-02-01T17:37:13+00:00 monthly 0.8 https://www.ematologiainprogress.it/acute-myeloid-leukemia-ontogeny-is-defined-by-distinct-somatic-mutations/ 2022-02-01T17:36:34+00:00 monthly 0.8 https://www.ematologiainprogress.it/le-mutazioni-di-idh1-e-idh2-inducono-dipendenza-da-bcl-2-nella-leucemia-mieloide-acuta-lam/ 2022-02-01T17:36:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/i-nuovi-farmaci-nel-mieloma-multiplo/ 2018-02-09T15:35:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/smouldering-multiple-myeloma-smm/ 2017-05-16T17:07:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/evoluzione-clonale/ 2017-05-16T17:07:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/gammopatia-monoclonale-di-incerto-significato-mgus/ 2017-05-16T17:08:28+00:00 monthly 0.8 https://www.ematologiainprogress.it/ash-meeting-2014-novita-sulle-lal/ 2026-04-01T12:42:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/dal-congresso-dellash-2014-eritroferrone-e-activin-ligand-traps/ 2026-04-01T12:42:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/llc-con-delezione-17p13-eo-mutazione-di-tp53-2/ 2020-01-08T10:12:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfomi-non-hodgkin-altamente-aggressivi-double-e-triple-hit-lymphomas/ 2017-05-16T17:24:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-ruolo-della-pet-nella-diagnosi-e-nel-monitoraggio-dei-linfomi-non-hodgkin-2/ 2020-01-08T14:54:49+00:00 monthly 0.8 https://www.ematologiainprogress.it/ruolo-della-bendamustina-nel-trattamento-dei-linfomi-non-hodgkin-2/ 2020-01-08T15:23:23+00:00 monthly 0.8 https://www.ematologiainprogress.it/mastocitosi-novita-dal-congresso-ash-2014/ 2026-04-01T12:42:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-in-tema-di-lam-dal-programma-educazionale-dellash-2014/ 2026-04-01T12:42:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/ash-2014-abstract-piu-importanti-in-tema-di-terapia-della-lam/ 2026-04-01T12:42:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-da-ash-2014-neoplasie-mieloproliferative-croniche-philadelphia-negative/ 2026-04-01T12:42:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-sulla-llc-dal-congresso-della-societa-americana-di-ematologia-ash-2014-lo-scenario-che-cambia/ 2026-04-01T12:42:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/le-infezioni-nei-pazienti-con-malattie-ematologiche-maligne/ 2017-05-17T13:04:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/ash-2014-primi-risultati-del-protocollo-gimema-lal-1509/ 2026-04-01T12:42:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/ifn-tipo-i-ed-efficacia-delle-antracicline/ 2014-12-11T17:17:13+00:00 monthly 0.8 https://www.ematologiainprogress.it/efficacia-del-mantenimento-con-rituximab-per-le-vasculiti-anca-associate/ 2014-12-10T15:48:35+00:00 monthly 0.8 https://www.ematologiainprogress.it/progetto-campus-primo-appuntamento-di-roma/ 2014-12-15T12:23:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/progetto-campus-secondo-appuntamento-di-orbassano/ 2014-10-20T14:03:22+00:00 monthly 0.8 https://www.ematologiainprogress.it/remissioni-durevoli-di-lal-con-linfociti-t-chimerici/ 2014-10-16T16:39:18+00:00 monthly 0.8 https://www.ematologiainprogress.it/cd30-e-immunoterapia-anti-cd30-nel-linfoma-di-hodgkin-anti-cd30-nel-linfoma-di-hodgkin/ 2020-01-10T10:26:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/ruolo-del-microambiente-nel-linfoma-di-hodgkin/ 2020-01-10T11:03:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/potenziali-target-terapeutici-nella-lal-ph-like/ 2014-10-13T10:08:21+00:00 monthly 0.8 https://www.ematologiainprogress.it/progetto-campus-il-primo-evento-dedicato-alla-lmc/ 2014-10-20T13:50:26+00:00 monthly 0.8 https://www.ematologiainprogress.it/terapia-del-mm-nellera-dei-nuovi-farmaci-due-nuovi-studi-randomizzati/ 2014-09-08T16:32:01+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2014-best-abstracts/ 2014-08-18T14:20:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/dalteparina-pre-partum-non-riduce-le-complicanze-nelle-donne-con-trombofilia/ 2014-07-31T15:27:09+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2014-brentuximab-nel-linfoma-di-hodgkin/ 2017-05-18T09:46:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2014-linfoma-mantellare-news-dalleha/ 2017-05-18T09:46:26+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2014-rituximab-s-c-nel-linfoma-follicolare/ 2017-05-18T09:46:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2014-unmet-need-in-dlbcl/ 2017-05-18T09:46:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/sie-2013-linfoma-b-mediastinico/ 2017-05-18T09:47:07+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2014-nuovi-anticoagulanti-orali/ 2017-05-18T09:47:14+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2014-grandi-novita-positive-nella-terapia-della-llc/ 2017-05-18T09:47:21+00:00 monthly 0.8 https://www.ematologiainprogress.it/malattie-mieloproliferative-croniche/ 2017-05-18T09:47:33+00:00 monthly 0.8 https://www.ematologiainprogress.it/terapia-dei-pazienti-con-mieloma-non-candidabili-al-trapianto/ 2017-05-18T09:47:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/azacitidina-nella-lam-dellanziano-con-30-di-blasti-midollari/ 2015-08-31T16:35:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2014-piastrinopenie-immuni/ 2017-05-18T09:47:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2014-terapia-genica-nelle-immunoglobulinopatie/ 2017-05-18T09:48:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/milano-xix-congresso-eha/ 2017-05-18T09:48:13+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2014-meeting-report/ 2017-05-18T09:48:20+00:00 monthly 0.8 https://www.ematologiainprogress.it/eha-2014-lunch-debate/ 2017-05-18T09:48:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/elacitarabina-nuova-formulazione-di-ara-c-non-migliora-loutcome-nella-lam-recidivata/ 2014-06-12T11:44:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-acuta-mieloide-le-alte-dosi-di-ara-c-in-induzione-aumentano-la-sopravvivenza/ 2014-05-21T15:25:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/blinatumomab-nella-leucemia-acuta-linfoide/ 2020-01-08T17:17:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-acuta-linfoide-a-cellule-b-maturelinfoma-burkitt-type-2/ 2020-01-08T17:45:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/le-mutazioni-del-gene-calreticulina-2/ 2017-03-20T13:39:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuova-stratificazione-prognostica-clinica-molecolare-delle-lam/ 2014-06-11T17:33:21+00:00 monthly 0.8 https://www.ematologiainprogress.it/mutazioni-e-prognosi-nella-mielofibrosi/ 2014-05-07T14:59:20+00:00 monthly 0.8 https://www.ematologiainprogress.it/le-mutazioni-del-gene-calreticulina/ 2014-05-07T14:59:33+00:00 monthly 0.8 https://www.ematologiainprogress.it/sirolimus-post-hct-reduce-la-gvhd-ma-non-migliora-la-sopravvivenza-nella-lal-pediatrica/ 2014-04-09T16:17:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/guida-al-portale/ 2021-10-04T13:18:00+00:00 monthly 0.8 https://www.ematologiainprogress.it/campus/ 2021-10-04T13:17:09+00:00 monthly 0.8 https://www.ematologiainprogress.it/prova/ 2021-10-04T13:22:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/mattioli-1885/ 2021-10-04T13:20:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/piano-opera/ 2026-06-23T09:21:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/tank/ 2021-10-04T13:24:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/iscrizione-newsletter/ 2021-10-04T13:18:07+00:00 monthly 0.8 https://www.ematologiainprogress.it/ash-2013-meeting-report/ 2026-04-01T12:42:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/trattamento-con-brentuximab-vedotin-di-pazienti-con-linfoma-t-anaplastico-a-grandi-cellule-sistemico-ricaduto-o-refrattario-follow-up-a-3-anni/ 2014-04-09T13:19:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/genetica-di-ptx3-e-rischio-di-aspergillosi-nel-hsct/ 2014-02-19T14:07:26+00:00 monthly 0.8 https://www.ematologiainprogress.it/rilevanza-clinica-di-piccoli-sottocloni-con-tp53-mutato-nella-llc/ 2014-02-19T14:07:14+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-mieloide-acuta-lam-report-dallash-2013/ 2026-04-01T12:42:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/profilassi-anti-d-prenatale-di-routine-nuove-linee-guida-bcsh/ 2014-01-30T13:44:23+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-linfatica-cronica-novita-dallash-2/ 2026-04-01T12:42:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/citofluorimetria-nelle-smd-e-nel-mm/ 2017-03-21T14:21:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-leucemia-acuta-promielocitica-nelladulto/ 2020-01-09T16:24:01+00:00 monthly 0.8 https://www.ematologiainprogress.it/obinutuzumab-efficace-in-associazione-con-clorambucil-nei-pazienti-con-llc-e-comorbidita/ 2014-01-17T10:03:09+00:00 monthly 0.8 https://www.ematologiainprogress.it/disclaimer/ 2021-10-04T13:17:21+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfoma-b-diffuso-a-grandi-cellule/ 2017-03-20T13:31:43+00:00 monthly 0.8 https://www.ematologiainprogress.it/trattamento-dei-linfomi-non-hodgkin-nei-pazienti-anziani-e-unfit/ 2020-01-08T15:41:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/efficacia-del-trattamento-profilattico-con-rfixfc-a-lunga-emivita-nellemofilia-b/ 2013-12-13T14:54:21+00:00 monthly 0.8 https://www.ematologiainprogress.it/ruolo-delle-alterazioni-dei-telomeri-nella-leucemia-linfatica-cronica/ 2020-01-08T11:09:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfocitosi-b-monoclonale/ 2020-01-08T12:04:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/trapianto-autologo-in-1-remissione-nei-nhl-aggressivi-in-quali-pazienti/ 2013-11-25T15:12:40+00:00 monthly 0.8 https://www.ematologiainprogress.it/alessandro-m-vannucchi/ 2021-10-04T13:16:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/enrica-orsini/ 2021-10-04T13:17:34+00:00 monthly 0.8 https://www.ematologiainprogress.it/lymphomas/ 2017-03-20T13:31:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/follicular-lymphomas/ 2017-03-20T13:31:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/ponatinib-per-il-superamento-della-resistenza-nelle-leucemie-ph/ 2013-11-22T17:52:13+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-ruolo-della-citofluorimetria-nella-diagnostica-dei-linfomi-non-hodgkin/ 2020-01-08T15:55:42+00:00 monthly 0.8 https://www.ematologiainprogress.it/utilizzo-di-rituximab-nei-pazienti-con-infezione-da-virus-dellepatite-b/ 2020-01-08T16:13:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/itp-ruolo-dei-cd8-nella-mancata-risposta-al-rituximab-2/ 2013-11-22T17:52:21+00:00 monthly 0.8 https://www.ematologiainprogress.it/brincidofovir-cmx001-per-la-prevenzione-delle-infezioni-da-cmv-post-sct-2/ 2013-11-22T17:52:28+00:00 monthly 0.8 https://www.ematologiainprogress.it/effetto-inibitorio-di-ruxolitinib-sulle-cellule-dendritiche-2/ 2013-11-22T17:52:35+00:00 monthly 0.8 https://www.ematologiainprogress.it/utile-trattare-i-pazienti-con-mm-smoldering-2/ 2014-04-09T14:33:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/atra-e-arsenico-senza-chemioterapia-per-la-lap/ 2013-11-22T17:52:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-mieloide-acuta-novita-cliniche-emerse-dal-congresso-della-european-hematology-association-stoccolma-giugno-2013/ 2014-04-09T14:34:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/determinanti-genetici-di-resistenza-alla-fludarabina-nella-llc/ 2013-11-22T17:53:12+00:00 monthly 0.8 https://www.ematologiainprogress.it/caratterizzazione-clinico-biologica-delle-lla/ 2013-11-22T17:53:21+00:00 monthly 0.8 https://www.ematologiainprogress.it/ibrutinib-nella-lcc-e-nel-mcl-verso-una-terapia-mirata-delle-emopatie-maligne/ 2013-11-22T17:53:28+00:00 monthly 0.8 https://www.ematologiainprogress.it/r-chop-14-per-dlbcl-no-vantaggi-su-r-chop-21/ 2013-11-22T17:53:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/utilita-della-trasfusione-profilattica-di-piastrine-nei-pazienti-con-neoplasie-ematologiche/ 2013-11-22T17:53:48+00:00 monthly 0.8 https://www.ematologiainprogress.it/livello-di-t315i-e-risposta-ai-tki-nella-lmc/ 2014-04-09T14:35:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/standardizzazione-dei-sintomi-emorragici-nella-itp/ 2014-04-09T14:35:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/duloxetina-per-la-neuropatia-periferica-indotta-da-chemioterapia/ 2013-11-22T17:54:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/bendamustina-e-rituximab-verso-r-chop-nei-linfomi-indolenti/ 2013-11-22T17:54:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/pomalidomide-e-desametasone-nel-mm/ 2014-04-09T14:36:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/mantenimento-post-asct-con-talidomide-e-prednisone-nel-mm/ 2013-11-22T17:54:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-dallash-2012-terapia-della-leucemia-mieloide-acuta-lam/ 2026-04-01T12:42:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/utilita-del-doppio-trapianto-di-cordone-negli-adulti/ 2013-11-22T17:55:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/long-term-eltrombopag-nella-itp-risultati-dello-studio-extend/ 2014-04-07T17:37:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/terapia-con-fattore-viii-e-inibitori-nellemofilia-a/ 2013-11-22T17:57:33+00:00 monthly 0.8 https://www.ematologiainprogress.it/molecular-profiling-per-la-classificazione-dei-linfomi-t-periferici/ 2014-04-07T17:37:41+00:00 monthly 0.8 https://www.ematologiainprogress.it/un-nuovo-modello-prognostico-integrato-mutazionale-citogenetico-per-la-leucemia-linfatica-cronica/ 2013-11-22T17:56:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/eventi-cardiovascolari-e-intensita-del-trattamento-nella-pv/ 2014-04-07T17:37:55+00:00 monthly 0.8 https://www.ematologiainprogress.it/tp53-e-prognosi-nei-dlbcl-trattati-con-r-chop/ 2013-11-22T17:57:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/cellule-staminali-periferiche-verso-midollari-nei-trapianti-allogenici/ 2014-04-07T17:38:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/utilizzo-di-inotuzumab-ozogamicin-nelle-leucemie-linfoblastiche-acute-refrattariein-recidiva/ 2013-11-22T17:56:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/trasfusione-di-piastrine-profilattica-o-terapeutica/ 2013-11-22T17:57:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/efficacia-di-midostaurina-inibitore-di-flt3-nelle-lam-allesordio/ 2014-04-07T17:38:20+00:00 monthly 0.8 https://www.ematologiainprogress.it/impatto-del-peso-corporeo-sulla-prognosi-dei-pazienti-adulti-con-lam/ 2014-04-07T17:38:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/efficacia-di-carfilzomib-nel-mieloma-multiplo-allesordio/ 2014-04-07T17:38:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuovo-ipss-per-le-mielodisplasie/ 2014-04-07T17:38:49+00:00 monthly 0.8 https://www.ematologiainprogress.it/trattamento-dei-pazienti-anziani-con-linfoma-mantellare/ 2013-11-22T17:57:01+00:00 monthly 0.8 https://www.ematologiainprogress.it/consolidamento-con-vtd-superiore-a-td-dopo-abmt-nel-mm/ 2014-04-07T17:38:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/radioterapia-per-i-bambini-con-hodgkin-a-basso-rischio/ 2013-11-22T17:58:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-dal-17-eha/ 2014-04-07T17:39:09+00:00 monthly 0.8 https://www.ematologiainprogress.it/efficacia-di-eltrombopag-nellanemia-aplastica-refrattaria/ 2014-04-07T17:39:19+00:00 monthly 0.8 https://www.ematologiainprogress.it/baecopp-a-ridotta-intensita-nellhodgkin-avanzato/ 2014-04-07T17:39:32+00:00 monthly 0.8 https://www.ematologiainprogress.it/immunoterapia-genica-per-la-llc/ 2014-04-07T17:39:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/mantenimento-con-lenalidomide-nel-mm-nuove-evidenze-cliniche/ 2014-04-07T17:39:54+00:00 monthly 0.8 https://www.ematologiainprogress.it/efficacia-di-gemtuzumab-nella-lam-allesordio/ 2014-04-07T17:40:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/novita-nel-trattamento-della-splenomegalia-nella-mielofibrosi/ 2014-04-07T17:40:14+00:00 monthly 0.8 https://www.ematologiainprogress.it/blinatumomab-in-pazienti-con-leucemia-acuta-linfoblastica/ 2014-04-07T17:40:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/profilassi-della-vod-con-defibrotide-nei-trapianti-pediatrici/ 2013-11-22T17:58:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/genesi-e-prognosi-delle-lam-analisi-del-profilo-genetico/ 2014-04-07T17:40:35+00:00 monthly 0.8 https://www.ematologiainprogress.it/alterazioni-di-birc3-e-chemioresistenza-alla-fludarabina-nella-llc/ 2014-04-07T17:40:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/fludarabina-e-rituximab-per-hcl-refrattariarecidivante/ 2014-04-07T17:40:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/ruxolitinib-inibitore-di-jak2-per-la-mielofibrosi/ 2013-11-22T17:58:01+00:00 monthly 0.8 https://www.ematologiainprogress.it/lal-negli-infanti-valore-prognostico-del-gep/ 2014-04-07T17:41:03+00:00 monthly 0.8 https://www.ematologiainprogress.it/stratificazione-genetica-del-rischio-nella-lam/ 2013-11-22T17:57:41+00:00 monthly 0.8 https://www.ematologiainprogress.it/associazione-fra-cd8pd-1-e-progressione-di-malattia-nella-llc/ 2014-04-07T17:41:14+00:00 monthly 0.8 https://www.ematologiainprogress.it/possibile-abvd-senza-radioterapia-nellhd/ 2014-04-07T17:41:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/brentuximab-vedotin-per-cd30-hd-recidivatoresistente/ 2014-04-07T17:41:36+00:00 monthly 0.8 https://www.ematologiainprogress.it/clinical-news-from-ash-2011-leucemia-mieloide-acuta/ 2026-04-01T12:42:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/genetica-della-llc-dei-linfomi-e-della-lma/ 2014-04-07T17:41:55+00:00 monthly 0.8 https://www.ematologiainprogress.it/ofatumumab-efficace-nella-llc-resistente-al-rituximab/ 2014-04-07T17:42:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/chemioterapia-pediatric-like-per-adulti-con-lla/ 2014-04-07T17:42:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/lenalidomide-attiva-nei-pazienti-con-hd-recidivato/ 2014-04-07T17:42:28+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-genomica-rivela-un-nuovo-marcatore-della-leucemia-linfatica-cronica-ad-alto-rischio-le-mutazioni-di-sf3b1/ 2014-04-07T17:42:52+00:00 monthly 0.8 https://www.ematologiainprogress.it/gentuzumab-ozogamycin-nella-leucemia-mieloide-acuta-una-never-ending-or-ended-story/ 2014-04-07T17:43:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/dasatinib-as-first-line-treatment-for-adult-patients-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/ 2014-04-07T17:43:14+00:00 monthly 0.8 https://www.ematologiainprogress.it/sequenziamento-del-genoma-nella-llc-commento/ 2013-11-22T17:57:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/mutazioni-di-braf-nella-hairy-cell-leukemia/ 2014-04-07T17:43:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/report-from-bioiron-2011-the-fourth-congress-of-the-international-bioiron-society-ibis/ 2013-11-22T17:58:09+00:00 monthly 0.8 https://www.ematologiainprogress.it/valutazione-prognostica-a-lungo-termine-secondo-la-classificazione-eln-di-pazienti-con-leucemia-mieloide-acuta/ 2013-11-22T17:56:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/news-dalleha-ruxolitinib-per-la-mielofibrosi-idiopatica/ 2014-04-07T17:43:48+00:00 monthly 0.8 https://www.ematologiainprogress.it/outcome-dei-pazienti-con-leucemia-mieloide-acuta-e-cariotipo-monosomico-sottoposti-a-trapianto-allogenico-di-cellule-staminali-emopoietiche/ 2014-04-07T17:44:01+00:00 monthly 0.8 https://www.ematologiainprogress.it/e-utile-una-terapia-post-remissionale-intensiva-nella-lam-degli-anziani/ 2014-04-07T17:44:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/tossicita-ed-efficacia-di-cpx-351-in-pazienti-con-lam/ 2013-11-22T17:57:24+00:00 monthly 0.8 https://www.ematologiainprogress.it/utile-trattare-i-pazienti-con-mm-smoldering/ 2013-11-22T17:56:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfoma-follicolare/ 2016-01-26T17:44:59+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfoma-mantellare/ 2017-03-20T13:32:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/sie-2013-novita-sulla-llc/ 2017-03-20T13:26:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/sie-2013-novita-nella-terapia-della-llc/ 2017-03-20T13:26:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/sie-2013-mieloma-multiplo/ 2017-03-20T13:36:04+00:00 monthly 0.8 https://www.ematologiainprogress.it/glossary/ 2021-10-04T13:17:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/robin-foa/ 2021-10-04T13:22:57+00:00 monthly 0.8 https://www.ematologiainprogress.it/faculty/ 2026-04-24T11:34:33+00:00 monthly 0.8 https://www.ematologiainprogress.it/guido-finazzi/ 2014-04-07T17:45:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/tiziano-barbui/ 2014-04-07T17:45:33+00:00 monthly 0.8 https://www.ematologiainprogress.it/giovanni-rossi/ 2014-04-07T17:45:49+00:00 monthly 0.8 https://www.ematologiainprogress.it/francesco-dalo/ 2014-04-07T17:46:00+00:00 monthly 0.8 https://www.ematologiainprogress.it/gina-zini/ 2014-04-07T17:46:10+00:00 monthly 0.8 https://www.ematologiainprogress.it/daniela-cilloni/ 2014-04-07T17:46:21+00:00 monthly 0.8 https://www.ematologiainprogress.it/felicetto-ferrara/ 2014-04-07T17:46:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-lal-nelle-diverse-fasi-delleta-epidemiologia-e-prognosi/ 2017-03-20T13:06:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/tommaso-za/ 2014-04-07T17:46:44+00:00 monthly 0.8 https://www.ematologiainprogress.it/mario-boccadoro/ 2014-04-07T17:46:57+00:00 monthly 0.8 https://www.ematologiainprogress.it/giuseppe-saglio/ 2014-04-07T17:47:06+00:00 monthly 0.8 https://www.ematologiainprogress.it/antonio-cuneo/ 2014-04-07T17:47:17+00:00 monthly 0.8 https://www.ematologiainprogress.it/robin-foa/ 2014-04-07T17:47:28+00:00 monthly 0.8 https://www.ematologiainprogress.it/francesco-rodeghiero/ 2020-12-23T11:02:27+00:00 monthly 0.8 https://www.ematologiainprogress.it/clara-camaschella/ 2014-03-19T10:00:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/giovanni-pizzolo/ 2014-04-07T17:47:51+00:00 monthly 0.8 https://www.ematologiainprogress.it/trombosi-e-piastrinopenia-immune-primaria/ 2020-01-10T11:55:08+00:00 monthly 0.8 https://www.ematologiainprogress.it/pippo/ 2014-03-04T17:04:32+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-acuta-linfoide-ph/ 2020-01-09T10:40:58+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfomi-t-prof-francesco-damore/ 2017-03-20T13:32:22+00:00 monthly 0.8 https://www.ematologiainprogress.it/le-leucemie-mieloidi-acute-secondarie/ 2020-01-10T09:49:29+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-terapia-della-leucemia-mieloide-acuta-refrattaria/ 2020-01-10T10:01:00+00:00 monthly 0.8 https://www.ematologiainprogress.it/condizioni-cliniche-particolari/ 2018-02-14T10:02:07+00:00 monthly 0.8 https://www.ematologiainprogress.it/terapie-di-consolidamento-e-terapie-sperimentali/ 2017-03-20T13:28:07+00:00 monthly 0.8 https://www.ematologiainprogress.it/importanza-prognostica-e-problemi-nella-terapia-della-llc/ 2017-03-20T13:26:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/lesioni-citogenetico-molecolari-nella-llc/ 2017-03-20T13:27:11+00:00 monthly 0.8 https://www.ematologiainprogress.it/disordini-del-metabolismo-del-ferro-2/ 2017-03-20T13:04:47+00:00 monthly 0.8 https://www.ematologiainprogress.it/percorsi-diagnostici-e-risorse-economiche/ 2017-03-20T13:38:25+00:00 monthly 0.8 https://www.ematologiainprogress.it/eccesso-di-epdicina-sideropenia-e-anemia-sideropenica/ 2017-03-20T13:04:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/cosa-ci-si-aspetta-dalla-ricerca/ 2017-03-20T13:06:14+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-cromosoma-philadelphia-oggi/ 2017-03-20T13:06:30+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuove-prospettive-terapeutiche-per-la-lmc/ 2017-03-20T13:28:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/morbilitaa-dellintervento-di-splenectomia/ 2020-01-10T12:15:00+00:00 monthly 0.8 https://www.ematologiainprogress.it/imatinib-e-terapia-di-seconda-linea/ 2017-03-16T13:21:57+00:00 monthly 0.8 https://www.ematologiainprogress.it/biologia-molecolare-e-citogenetica/ 2017-03-20T13:38:32+00:00 monthly 0.8 https://www.ematologiainprogress.it/malattia-minima-residua/ 2017-03-20T13:06:22+00:00 monthly 0.8 https://www.ematologiainprogress.it/sindromi-mieloproliferative-croniche-tiziano-barbui/ 2019-05-08T16:49:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/piattaforma-diagnostica/ 2017-03-20T13:38:38+00:00 monthly 0.8 https://www.ematologiainprogress.it/analisi-del-sangue-periferico-nella-diagnosi-ematologica-2/ 2017-03-20T13:38:45+00:00 monthly 0.8 https://www.ematologiainprogress.it/nuovi-parametri-strumentali/ 2018-02-14T10:55:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/referto-strumentale-sysmex-xe-2100/ 2017-03-21T14:21:35+00:00 monthly 0.8 https://www.ematologiainprogress.it/referto-strumentale-siemens-advia-2120/ 2017-03-21T14:21:42+00:00 monthly 0.8 https://www.ematologiainprogress.it/referto-strumentale-beckman-coulter-serie-lh/ 2017-03-21T14:21:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/referto-strumentale-abbott-celldyn-sapphire/ 2017-03-21T14:21:56+00:00 monthly 0.8 https://www.ematologiainprogress.it/disordini-da-difetto-di-epcidina/ 2017-03-20T13:05:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-mieloide-cronica-2/ 2017-03-20T13:29:10+00:00 monthly 0.8 https://www.ematologiainprogress.it/classificazione-dei-linfomi-non-hodgkin/ 2017-03-20T13:32:16+00:00 monthly 0.8 https://www.ematologiainprogress.it/inquadramento-odierno-delle-lal/ 2017-03-20T13:06:42+00:00 monthly 0.8 https://www.ematologiainprogress.it/diagnosi-e-terapie-di-induzione-nella-lam/ 2017-03-20T13:28:15+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfomi-t-prof-paolo-corradini/ 2017-03-20T13:32:31+00:00 monthly 0.8 https://www.ematologiainprogress.it/leucemia-linfatica-cronica-parte-1/ 2017-03-20T13:27:50+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfoma-non-hodgkin-2/ 2017-03-20T13:32:39+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-trapianto-di-cellule-staminali-emopoietiche-nei-linfomi-non-hodgkin/ 2020-01-08T16:49:05+00:00 monthly 0.8 https://www.ematologiainprogress.it/il-ruolo-fisiologico-dell-epcidina/ 2017-03-20T13:05:13+00:00 monthly 0.8 https://www.ematologiainprogress.it/la-sindrome-da-lisi-tumorale/ 2020-01-08T16:54:33+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfomi-aggressivi-b-prof-maurizio-martelli/ 2017-03-20T13:32:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/linfomi-follicolari-prof-umberto-vitolo/ 2017-03-20T13:32:53+00:00 monthly 0.8 https://www.ematologiainprogress.it/aml-all-eu-focus-meeting-2024-56315/ 2024-12-16T07:39:46+00:00 monthly 0.8 https://www.ematologiainprogress.it/ 2026-08-14T12:01:33+00:00 monthly 1